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This study sought to examine the extent to which technology influences operational performance 
of pharmaceutical firms in Kenya. The objectives for this study were to test the relationship 
between; level of technology, supply chain technology, marketing technology and quality control 
technology and operational performance of pharmaceuticals firms in Kenya. The study was 
anchored on Diffusion of Innovation Model and Technology Acceptance Model (TAM). There 
are 50 registered pharmaceutical firms operating in Nairobi and unit of analysis were all persons 
who were working in four departments; Supply Chain, Marketing, Quality control and 
Operations in those firms. The study adopted cross-sectional survey design which supported 
identification of 200 respondents by use of purposive random sampling technique. 
Questionnaires were used to collect data from Operations Manager, Supply Chain Manager, 
Marketing Manager and Quality control Manager from the Pharmaceutical firms in Nairobi. The 
quality of this study was guaranteed by testing validity and reliability of the questionnaire. Data 
was analysed using computer supported software Statistical Package for Social Sciences (SPSS) 
to generate means, correlation and regression coefficients. The findings on level of technology 
revealed that with mean of 3.54, the level of technology was considered high. Also, with an 
overall mean of 3.21, the findings indicated that technology was intensively used in all stages of 
supply chain mainly in planning, implementation and reporting. Preliminary tests of assumptions 
were run; linearity tests, normality tests, multicollinearity tests    and homoscedasticity tests   and 
the results provided a basis for running parametric inferential statistics. The results of persons 
correlation coefficient indicate that there is a significant positive correlation between supply 
chain technology, marketing technology and quality control technology and operation 
performance whereas; a significant positive correlation between marketing technology with 
operation performance positive significant correlation between quality control technology and 
operation performance. Multiple regression analysis was run to test if the technology usage 
significantly predicts operation performance of pharmaceutical firms. The results of the 
regression indicated that the three predictors, supply chain, marketing and quality control 
explained 31.6% of operation performance could be explained by a unit change in supply 
technology on marketing technology the model established that 35.5% operation performance 
could be influenced by a unit change in marketing technology and finally, 38.2% of quality 
control technology would influence operation performance. Overall, the consistency of 
regression coefficients on the predictors in the model suggest that these variables are important 
factors influencing operation performance and therefore proving the usefulness of enhancing 
operational performance of pharmaceutical firm through the use of technology in departments 
like supply chain, quality control and marketing department for general improvement of 





1.1 Background to the Study 
Technology is increasingly becoming a strategy of improving performance of an organisation. 
Thompson, Strickland and Gamble (2007), observed that good strategy making builds a market 
position that is strong enough to make organization up its performance despite competition. 
Through adoption of Radio Frequency Identification (RFID) technology, a company can 
effectively monitor every product both at the production line and in the supply line. RFID chips 
are placed on all items which helps employees to quickly detect any anomalies in an order. It is 
an innovative way of correcting a problem before it ruins the entire supply chain.  
 
In transportation, modern technology includes the ingenious on-board truck scales which allow 
for seamless operations when access to platform scales is not available. The scales measure 
payload weight and the trucks gross weight and enhance productivity by ensuring a truck carries 
the maximum weight right from the point of loading while also saving time and money. Orembo 
(2013) found that on-board truck scales have also been adopted as a safety guarantee to ensure 
operators within a warehouse for instance only carry the allowed weight on their 
lifts. Computerized supplies management is the future of the business. Williams (2006) stated 
that use of computerized shipping and tracking software systems helps to integrate all operations 
from one panel and it enhances customer experience and reduces errors in the entire process.  
 
Social Media Revolution is an ingenious way to open more channels and remain in touch in real-
time with all stakeholders in the supply chain. It is easy to respond to questions, report in real-
time about incidences in the supply chain, report price changes, and also enhance visibility of the 
company. The usage of Information Technology (IT) in organizations across the supply chain 
has become a determinant of competitive advantage for many corporations. IT plays an enabler 
role in Supply Chan Management (SCM), by addressing a range of different point and enterprise 
solutions in a variety of supply chain settings (Venkatraman & Henderson, 1998). Emerging IT 
trends like software agents, RFID, web services, virtual supply chains, electronic commerce, and 




Some pharmaceutical industries are already using innovative marketing technologies which 
include webinars, video conferencing and streaming of international medical conferences to train 
local doctors and other health practitioners on new / innovative practices. This facilitates 
dissemination of the latest industry trends and provision of fast and cost-efficient marketing tool. 
Technology application is thus leveraged to train and build capacity for a high number of doctors 
as opposed to having a few senior doctors travel to developed world at high costs to attend the 
training. Technology has also been used to great effect to combat stock outs and anticipated 
demand for drugs to ensure constant and consistent supply year-round (Onyango, 2016).   
Omwansa (2012) observed that supplier integration software used by established drug retail 
stores directly feed information from the retail tills directly to the production units that ensure 
needed meds are available on demand. Dis- chem used by large pharmaceuticals in South Africa 
has reduced lead times as well as better stock units management through the information 
platform between customers and suppliers is constantly updating and monitoring the entire 
supply chain and enhancing overall performance.   
 
Other than use of technology in operations of pharmaceutical firms, technology is also applied 
by regulatory bodies of the pharmaceutical industry. For example, in Zimbabwe, Uganda, and 
Zambia, technology is used by respective pharmaceutical regulatory bodies (WHO, 2017). The 
regulatory services include license renewals, payments, clinical trials, students’ registration, 
trade, inspection, and verification of professionals has now moved online. The automation has 
reduced delays in service delivery and increased the capacity to transform pharmaceutical 
practice. The automation has also boosted revenue collection and improved industry surveillance 
mechanisms, (PPB, 2017). Payments can be easily done through electronic money transfer 
services. The new technology-based services have enabled the regulatory bodies in Zimbabwe, 
Uganda, and Zambia join Medicines Control Council of South African (MCC). MCC is the only 
pharmaceutical regulatory authorities in the continent which receive submissions of drug 
registration dossiers online, commonly referred to as Electronic Common Technical Document 
(E - CTD). 
 
In Kenya, health and ICT are slowly becoming more interconnected with the country proving a 
front-runner in innovative ICT solutions. Kenya is the only African country with a 
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comprehensive e-Health strategy and a ranked global power with a multi-billion United States 
Dollars (USD) turnover of mobile money (MPesa) payments that is increasingly being linked to 
paying for healthcare services. In Kenya, the Pharmacy and Poisons Board (PPB) was the first 
fully automated national drug regulatory authority in Africa in 2015, automating clinical trial 
registry process among other services. This certifies Kenya as a regional center of regulatory 
excellence for pharmaco-vigilance, a platform that tracks and reports adverse effects licensed 
drugs may have on patients. The PPB provides a list of all registered pharmacists online to help 
Kenyans easily identify qualifications of people superintending over pharmacies. While not full 
proof, the system has gone a long way in improving adherence and operational standards within 
the industry, (PPB, 2017). This coupled with Global Positioning System (GPS) enabled devices 
for enhanced drug and facility inspection have all served to increase transparency and efficiency 
at the regulator.  
 
Pharmaceutical firms in Kenya can be divided into three main segments namely; manufacturers, 
distributors and retailers. All these play a major role in supporting the country’s health sector, 
which is estimated to have about 4,557 health facilities countrywide according to the Ministry of 
Health (2016). The industry has major Multi-national pharmaceutical companies present through 
locally incorporated affiliates, technical representative offices and local technical agents. It also 
has local manufacturers and local importers of drugs as its membership all of whom then 
distribute their products through appointed distributors. Pharmaceutical products in Kenya are 
distributed through pharmacies, chemists, health facilities and shops. There are about 700 
registered wholesale and 3000 retail dealers in Kenya, manned by registered pharmacists and 
pharmaceutical technologists, a number that continues to increase as more players enter the 
sector, (PPB, 2017).  
 
A 2015 Business Monitor report on pharmaceutical manufacturing in Kenya states that the 
country hosts the largest pharmaceutical industrial base in East Africa. In Kenya, the 
pharmaceutical industry compounds and packages medicines, repackages formulated drugs and 
processes bulk drugs into doses using predominantly imported active ingredients and excipients. 
The bulk of locally manufactured preparations are non-sterile, Over the Counter (OTC) products. 
WHO (2014) noted that the Kenyan market for pharmaceuticals reached $558.5 million in 2014 
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with the total turnover for the local production standing it at $103 million. The value addition 
from the pharmaceutical sector generated around $62 million, an amount that has steadily risen 
since. The industry generally operates under the Ministry of Health however its members are in a 
lobby; The Kenya Association of Pharmaceutical Industries (KAPI) established in the 1960’s by 
a group of Research and Development (R&D) based pharmaceutical companies to promote high 
standards in the pharmaceutical industry. The Association draws its membership from large 
MNCs with local affiliates. KAPI’s mission is to promote an ethical, innovative and responsible 
health care industry. Of concern now is how the pharmaceutical sector can play its role 
efficiently and effectively.   
 
Another key player in the country’s pharmaceutical industry is the Kenya Pharmacy and Poisons 
Board which is the regulatory body under which the pharmaceutical firms in the country operate. 
Its mission is to protect the health of the public by regulating the profession of pharmacy and 
ensuring quality, safety and efficacy of medical products and health technologies in the country. 
The board’s main role is regulatory oversight of all players in the pharmaceutical industry (PPB, 
2017). The third key player in the country’s pharmaceutical industry is Kenya Medical Supplies 
Authority (KEMSA) which was established as a state corporation with the mandate to procure, 
warehouse and distribute medical commodities to Kenya’s Health facilities. KEMSA works to 
support the National Health Strategic Plan and the Kenya Health Package for Health in providing 
public health facilities with the right quantity and quality of drugs and medical supplies at the 
best market value, (KEMSA, 2007). KEMSA is the largest purchaser of drugs manufactured both 
locally and imported, in the country buying about 30% of the drugs in the Kenyan market 
through an open-tender system and distributing them to government medical institutions.  
 
The relationships between pharmaceutical firms, regulatory body and medical supply agency are 
important in promoting quality health care in the country. In this regard, supply and provision 
pharmaceutical products to consumers should be guaranteed by role of regulatory body. As 
technology promotes operational efficiency and effectiveness, technology thus becomes the link 
in regulation or control, supply and marketing in pharmaceutical firms in Kenya. However, it 
remains unclear how technology influences the operational efficiency of pharmaceutical firms in 
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Kenya. This study therefore sought to investigate the influence of technology on the operational 
performance of pharmaceutical firms in Kenya.  
1.1.1 Technology: Concept of independent variable 
Technology is the application of skills, competencies or mechanization for the purpose of 
enhancing efficiency and production quality while saving time and money (Orembo, 2013). 
Orembo explains technology as an application of scientific knowledge for practical purpose 
especially in industry with the purpose of enhancing efficiency in productivity. Technology may 
have tangible or intangible properties or both. Technological applications aim at facilitating task 
performance and speed-up in operations for more productivity in timelines. Technological 
innovations range from newly fabricated machinery, Information Communication Technology 
(ICT) systems which are tangible to intangible skills and competencies of human resources. 
Tangible technology applications improve quality, save time /speedup the flow of information or 
delivery of goods and services in firms. Vivarelli (2015) cites other benefits of business 
technology to include enhanced organizational efficiency in tracking supply chain in business 
relationships.  
 
According to Atalay, Anafarta and Sarvan (2013), technology and technological innovations 
have completely changed the business landscape; technological innovation is widely regarded as 
one of the most important sources of sustainable competitive advantage in an increasingly 
changing business environment. Its application leads to product and process improvements, 
makes continuous advances that help firms to survive, allow firms to grow faster, become 
efficient and ultimately become more profitable than non-innovators. Kotler (2000) observed that 
firms which fail to innovate put themselves at great risk of failure. In the pharmaceutical 
industry, technology is purported to be the basis of the industry since the industry’s very 
existence stems from the need to provide essential drugs to combat disease and improve general 
health and wellbeing. To achieve this, the industry relies heavily on technology to discover and 
improve new medicines over the years.  
 
Kotler (2001) postulates that globalization and rapid technological advancement have immensely 
transformed the way companies do business worldwide; spurred innovation and development in 
various sectors, and driven the world economic changes. Due to globalization, customers’ needs 
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and requirements have been changed and developed. Customers need the relevant product, in the 
right place, at the right time with high quality and affordable cost. Saleh (2015) observed that 
any organization seeking to compete in this recent hyper-market should match itself with the 
customers’ requirements. The pharmaceutical sector is complex and has many different 
interested parties including the manufacturers themselves, national regulators, government 
ministries, wholesalers among others, (UNIDO, 2010). To fully optimize its productivity implies 
embracing the industry as an asset to economic and social development which needs concerted 
action across the stakeholders. The pharmaceutical sector is complex with diverse stakeholders’ 
interests ranging from manufacturers themselves, national regulators, government ministries, 
wholesalers who require technological coordination (UNIDO, 2010).  
1.1.2 Operational Performance  
Operational performance is a measure of a firm’s performance against standards of effectiveness, 
efficiency and environmental responsibility which may include cycle time, productivity, waste 
reduction and regulatory compliance. It may be said to be a group of standards and benchmarks 
that are adopted and used by organizations to achieve competitive advantage, customer 
satisfaction, and maximum level of profitability. Operational efficiency is an essential 
component of organizational performance. Abdolvand, Albadvi and Ferdowsi (2012), in terms of 
outputs  based on quality of services and products, speed of product and service delivery, 
flexibility, and dependability. Operational performance may also be said to be the sum total of all 
an entity’s routine processes and activities, and the undertaking of these activities which can 
range from financial to being non-financial. Kalpan and Norton (2001) came up with a 
performance measure framework which gives organizations a balanced view of performance; 
under four perspectives; financial, customer, growth, and internal processes. In the 
pharmaceutical industry, operational performance may be derived as a function of cost reduction, 
revenue growth, ease of access of new products/ speed of launches and general product lead 
times. 
1.1.3 Pharmaceutical Industry   
The global pharmaceutical industry has continuously grown over the years and emerged as one 
of the fastest growing industries in the world. Its market worth is over US$1,200 billion a year, a 
figure that was expected to rise continually by the World Health Organisation (WHO) in a 2015 
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report. Controlling over one-third of this market, with sales over US$400 billion a year and profit 
margins of about 30%, are the 10 largest drug companies in the world, with six based in the 
United States and four in Europe.  Production and consumption within the industry is unevenly 
distributed around the world with the developed countries being the leading producers and 
consumers of pharmaceuticals. While they bear the heaviest disease burden, developing regions 
like Asia, Africa, Australia and Latin America with a share of nearly 85% of world population, 
only accounted for 21% of global pharmaceutical consumption in 2010 (IMS Health Market 
Prognosis, 2011). This was mainly due to the high cost associated with quality medication and 
other resultant factors that have worked in tandem to further exclude the poor from quality 
healthcare. 
 
Globally there is continual pressure on healthcare systems as players and governments with 
diminishing resources try to ensure affordable healthcare for all. UNIDO (2016) noted a global 
increase in Non-Communicable Diseases (NCDs) like Cancer, Diabetes and Hypertension not to 
mention more rare forms of illnesses e.g Multiple Sclerosis all of which are expensive to manage 
and as a result there is increasing strain on healthcare systems globally. Globally, firms view 
technology adoption as a means of improving their performance. Innovative technology is a 
major continuous management strategy undertaken by firms to increase efficiency, effectiveness 
and impact of the firms. Kotler (2000) observes that firms which fail to innovate put themselves 
at great risk of failure. 
 
Developing countries have an even bigger challenge with double disease burden where NCDs 
are on the rise while the burden of communicable diseases likes Malaria, Cholera etc still 
persistent. This is further compounded by poorly funded healthcare systems resulting in huge 
pricing pressures for pharmaceutical industry players that have to try to deliver on their mandate 
of service delivery while remaining as viable businesses. Within Africa South Africa has the 
most developed pharmaceutical industry with high specs on quality, regulatory processes and 
efficient supply chain systems right to the point of usage by patients/ consumers? This is partly 
driven by years of technology transfer by most international players who set hubs there to 




In East Africa, Kenya is the front runner with, and most advanced compared to its neighbours 
(Uganda, Tanzania, Burundi, Sudan, Ethiopia, and Rwanda). The pharmaceutical industry in 
Kenya plays a major role in supporting the health sector by providing medication for treatment 
and prevention of various diseases. This not only aids in management of diseases but also 
promotes good health of the citizenry to enable them to participate actively in the economics of 
nation building. To effectively play this role, the industry should support research-based 
production, marketing, promotion and availability of quality medication at the right place, time 
and quantities (Business Daily, 2017). 
Good quality medicine are still very expensive in this part of the world. With growing demand 
and poor enforcement of regulations coupled with unethical practices there’s a rise in 
proliferation of unregulated or “grey” medicines. These are pharmaceutical products brought into 
the market through irregular channels without undergoing the necessary regulatory scrutiny to 
conformity as stipulated by Pharmacy and Poisons Board. Such products pose dangers to the 
patients using them since their efficacy and quality remains questionable.  However due to their 
relatively lower prices, many consumers end up opting for them judging by relative costs based 
on limited incomes as well. 
The government of Kenya needs to provide incentives to encourage local production of 
affordable medicine particularly for simple molecules in a bid to drive growth of local 
manufacturing and exports to the regional market. It also needs to protect the interests of 
research based Multi-National Corporations (MNCs) which are key players in the 
pharmaceutical industry globally particularly on Research and Development of new drugs.  
Multinational corporations lead in supplying innovative molecules, latest interventional products 
available in the developed markets, patented medicines, new technologies and act as incubation 
hubs for latest pharmaceutical inventions all of which eventually feed the generic manufacturers 
(MOH, 2013).This delicate balancing act must be done deliberately by government if the 
potential inherent in the pharmaceutical industry is to be fully optimized.   Technology is a buzz 
word adopted by many as they strive to be competitive and this study will establish whether its 
just glamour or indeed a critical support with operational efficiency to improve competitiveness. 
1.2 Problem Statement 
As a developing nation, Kenya still suffers from a huge burden of communicable diseases (T.B, 
Malaria, Cholera, and HIV among others).  Current statistics show an increasing trend of Non- 
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Communicable Diseases (NCD’s), like Diabetes, Cancer and Hypertension. This situation is 
described as “double disease burden” with both Communicable diseases as well as NCD’s. This 
is a big strain on the healthcare system that’s inherently underfunded.  With a high disease 
burden and inadequate healthcare financing, the result is immense pricing pressure for quality 
medication. To improve on medication pricing, the pharmaceutical industry needs to increase 
competitiveness by allowing as many players with quality brands as possible in the market and 
the use of technology in process improvement and enhancing operational effectiveness and 
efficiency has been proposed by pharmaceutical industries in (Kenya (MOH, 2013).  
 
Marketing on average consumes one-third of total sales revenue of pharmaceutical products, this 
doubles the amount spent on research and development. This was mainly attributed to pressure to 
maintain sales which led to an inherent conflict of interest between the public selection and 
rational use of drugs.  Pharmaceutical companies incur huge costs associated with 
transcontinental travel by Physicians for the sole purpose of knowledge transfer. The push for 
sales and more profits has also compromised the quality controls. Whereas research and quality 
control should be given necessary priorities, pharmaceutical industries spend less on innovation 
but more on marketing to make more sales (WHO, 2013). The industry should explore means of 
leveraging on technology to facilitate the same knowledge transfer at cheaper costs. This would 
inevitably reduce the costs of investments and hence some price relief.  
 
Therefore, the role of technology in operational performance of pharmaceutical firms can be 
ascertained and confirmed by empirical studies. However, empirical evidence that will ensure 
pharmaceutical firms in Kenya increasingly adopt technology in operational activities remain 
inadequate. For example, use of technology had significant influence in supply chain of Postal 
Kenya (Jepkoech, 2012). Also, technology improves marketing in retail outlets (Munyasi, 2015; 
Ndubai, 2013) and distribution firms (Ngumau, 2016). On quality, technology was found to 
increase efficacy (Sigei, 2014), enforcement of regulatory framework (Kiragu, 2014) and 
financial performance (Mutua, 2014). The empirical evidence available does not exhaustively 
indicate that use of technologies in pharmaceutical firms improves operational efficiency in 
supply chain, marketing and quality control. It is with reference to the above issues that this 
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study sought to explore whether technology can be deployed to improve pharmaceutical firm 
performance.  
1.3 Research Objectives 
The overall objective of this study was to determine the influence of technology on the 
operational performance of pharmaceutical firms in Kenya. The study was guided by the 
following specific objectives: 
i. To establish the level of technology used by pharmaceutical firms in Kenya. 
ii. To determine the influence of supply chain technology on the operational performance of 
pharmaceutical firms in Kenya. 
iii. To determine the influence of marketing technology on the operational performance of 
pharmaceutical firms in Kenya. 
iv. To determine the influence of quality control technology on the operational performance 
of pharmaceuticals firms in Kenya. 
1.4 Research Questions 
This study attempted to answer the following research questions: 
i. What are the levels of technology used by pharmaceutical firms in Kenya?  
ii. To what extent has supply chain technology influenced operational performance of 
pharmaceutical firms in Kenya? 
iii. To what extent does marketing technology influence the operational performance of 
pharmaceutical firms in Kenya? 
iv. To what extent has quality control technology influence the operational performance of 
pharmaceutical firms in Kenya. 
1.5 Significance of the Study 
This study focused on pharmaceutical industry that directly touches on management of human 
health. Pharmaceutical industry is pivotal disease management and achievement of good health. 
The study will therefore be of benefit to pharmaceutical industry players as they seek to address 
the challenges of operational optimization. The findings on this study may inform way to 
optimize processes and improve efficiency across the pharmaceutical industry. The study will 
also be useful for future scholars who may be interested in this area of study as they can use the 
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study findings and recommendations as a basis for their research and to this end, it will have 
added to the wider body of knowledge and academic research.  
1.6 Scope of the Study 
The delimitation of this study was confined to pharmaceutical manufacturers in Kenya. Going by 
the latest registration they are 50 in total and this represents the total number of registered 
manufacturers (PPB Renewal 2019). Within each of the companies the study targeted a 
respondent from each of the following four departments: Supply Chain, Regulatory, Quality 
control and Operations.  The concentration of their operational bases is in Nairobi County hence 
the study was confined to Nairobi County.  The aim of the study was to establish the level of 
usage of technology by these firms and more specifically the influence of marketing, supply 
chain and quality control technologies on operational performance. The study was conducted 
between April and May 2019, and respondents provided information through a questionnaire 






















This chapter reviews literature on relevant past researchers and pertinent documents and working 
papers on influence of technology and perceived operational efficiency in pharmaceutical firms. 
The first section presents theoretical review while the second section provides empirical review 
which anchors the gap on which the study is focused. The review arrangement is consistent with 
independent variables used in the study.  The last section of the chapter presents the conceptual 
framework. 
2.2 Theoretical framework  
This study adopted two theoretical frameworks: Diffusion of Innovation Model (DOI) and 
Technology Acceptance Model (TAM). DOI was used to explain the phases in which technology 
diffuses into organization and finally adopted to support operations (supply, marketing, quality). 
TAM was also used to explain acceptance behaviour of organizations that adopt technologies to 
improve operations.  
2.2.1 Diffusion of Innovation Theory 
This study adopted the Diffusion of Innovation model. The Diffusion of Innovation (DOI) theory 
was introduced by Rogers in 1962 and states that ‘diffusion is the process of conveying 
innovation for a period to members of a society using certain channels. Rogers (2003) describes 
the series of phases through which an individual or firms go through in technology adoption. 
These are: the knowledge phase, persuasion phase, decision phase, implementation phase, and 
confirmation phase. Notions on the technology’s characteristics like compatibility, its relative 
advantage, complexity, observability, and trialability impact the adoption process. 
The knowledge phase is characterized by an individual learning about the existence of new 
technology and seeking information about it. At persuasion phase, the individual creates a 
negative or positive attitude towards the new technology, but such attitude does not always result 
in acceptance or rejection of the new technology. During the decision phase, the person chooses 
whether to take up and fully utilize the new innovation or to decline it. Implementation involves 
putting the new technology into practice, while at confirmation phase the individual seeks 
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approval for his/her decision (Oliveira & Martins, 2010). For the DOI model the individual, the 
structure of the organization and a firm’s external characteristics are important backgrounds to 
innovation (Oliveira & Martins, 2010). 
This model focuses on the driving force for the adoption of the technology. This implies that the 
motive or reason for adoption is based on expected outcomes of the technology in supporting 
businesses. According to this model, the decision made by people or organizations on whether to 
adopt a technology or not is heavily dependent on perceived influence of the technology. It is 
from such perceptions that there are categories of the people: early adopters, early majority, late 
majority and laggards. In this regard, early adopters become satisfied with the influence of the 
technology early enough as compared to the rest. Thus, if the technology offers quick solutions, 
it is easier to be adopted.  
According to this theory, pharmaceutical firms level of usage of technology was based on 
various technological fit in their processes and the motivating factor pushed by factors like how 
technology enhance speed, convenience in service delivery, boost in sales and effectiveness. In 
supply chain technology, firms use technology to share information through electronic supply 
network interphase such as Manufacturing Resource Planning (MRP) which enhance on time 
availability of the right materials required based on customers feedback and trend analysis of 
orders. Additionally, according to this theory technology supports quality control, monitoring old 
stocks to be released first and reduced firm’s losses as well as supporting marketing and 
increasing sales and revenue of the firms.   
2.2.2 Technology Acceptance Model 
Technology Acceptance Model (TAM) was developed by Fred Davis in 1989. The model states 
that adoption of any technology by firms or organization is significantly dependent on 
perceptions about usefulness and ease of use of the technologies. Davis (1989) defines perceived 
usefulness of technology as user’s conviction that using the technology is beneficial in terms of 
improving worthiness, performance or wellbeing. Also, Davis (1989) defines perceived ease of 
use of the technology as user’s conviction that using the technology will be free of effort. Based 
on the two definitions of perceived usefulness and ease of use of the technologies, the TAM 
indicates that the two factors define the behaviour of the user before adopting the technology. In 
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this regard, organizations that perceive technologies will improve overall performance end up 
adopting the technology. Also, organizations that perceive that any technology if applied will 
reduce costs and deployment of more resources eventually adopt such technology.  
  
In this study, Technology Acceptance Model (TAM) was applied in this study by acknowledging 
that the driving force for any technology adoption based on the applicability and the subsequent 
rewards of that technology to a pharmaceutical firm. This indicates that pharmaceutical firms 
that perceive technologies to be useful will increase overall operational performance are likely to 
be adopted. This study therefore used this theory to measure the extent to which operational 
performance of pharmaceutical firms in Kenya is influenced by perceptions about usefulness as 
well as ease of using these technologies.  
2.3 Empirical Review 
This section describes the review of empirical studies on level of technologies used by 
Pharmaceutical firms. The section also provides a description on supply chain and operational 
performance, marketing technology and operational performance as well as quality control 
technology and operational performance.  
2.3.1 Level of Technologies used by Pharmaceutical Firms 
Technology is revolutionizing the way Pharma industry conducts business globally. In Hungary, 
study done to investigate integration of knowledge management into information technology 
intelligence framework revealed that firms are utilising technology-based intelligence framework 
to improve integration of business intelligence initiatives. According to Boldeanu and Pugna 
(2012), the changes are affecting every level from Research and Development (R&D), 
interaction with Healthcare providers and patients to even healthcare systems in different 
markets. This indicates that with a cumbersome operational base, restrictive regulatory 
environment, cutthroat competition, pricing pressure and increasing bargaining power by both 
payers and consumers, Pharma companies are all struggling to keep up leveraging on 
technology. During the Research and development phase new technologies are being adopted 
into the drug development industry. This includes big data analysis to mine information from 




In Pakistan, a study was done to determine the factors that affect readiness for business process 
in pharmaceutical firms. According to Abdolvand, Albadvi and Ferdowsi (2012), pharmaceutical 
companies are leveraging technology to go further and faster in monitoring patient safety. It also 
helps reduce costs and promote efficiencies by reducing manual input. To enhance marketing 
activities technology is used in segmentation and targeting of both healthcare providers as well 
as consumers for targeted communication approaches. This informs the choice of media used for 
communication or even more specifically product type vs prescription habits and patient types 
seen by respective specialist approaches. Customer Relationship Management (CRM) tools are 
also increasingly used to monitor performance of field teams to drive the desired customer 
coverage and reach leveraged to drive coverage as well as performance management of business 
development teams/ Field force (Drennan & McColl-Kennedy, 2003)  
 
From the perspective of customers, a study was done in United States of America to determine 
the perception of patients on service delivery through technology. In the study, Porter (2010) 
opines thatwith literacy levels on the increase alongside access to information, patients are 
becoming more engaged in health issues. In the digital age, patients are much less dependent on 
their doctors for advice, increasingly able and willing to take greater control of their own health. 
They feel empowered by the vast amount of health information available online and on apps, and 
by the array of health and fitness wearables such as FitBit and Apple Watch. In one survey, more 
than 85 percent of patients said they were confident in their ability to take responsibility for their 
health and knew how to access online resources to help them do so. In addition, patients are 
becoming keener to evaluate different healthcare products and services given that they bear a 
growing proportion of the costs. To provide solutions to patients, Pharmaceutical companies 
must also engage digital with patients as they make such evaluations hence shifting the model of 
business. 
 
Like the ebays and Amazons of the world, pharmaceutical business is moving towards online. In  
Africa, while the pace is not as fast as the developed countries, there is gradual growth in use of 
technology for operations in pharmaceutical firms. For example, in Nigeria the technologies are 
used in marketing (Melodi, Olufayo & Gbadamosi, 2012). As such Kenya already have an online 
Pharmacy (MYDAWA). Pharmaceutical companies are being pushed to adopt these as 
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distribution channels. With increasing focus on product quality and efficacy, technology is being 
used for batch tracking, temperature control and even pharmacovigilance. However, how the 
pharmaceuticals have adopted the technologies in Kenya remains unknown empirically hence 
this study.   
2.3.2 Supply Chain Technology and Operational Performance 
Supply chain is a logistical arrangement of goods and services in the market place. Kotler and 
Armstrong (2012) defined distribution channel as an array of interdependent organizations in the 
marketplace that help, through their activities, make any product or service readily available for 
the use or consumption of the consumer or a business user. Supply chain management may be 
defined as the overall management of this distribution channel. Due to the product sensitivity of 
the pharmaceutical industry, the supply chain becomes an integral pillar that must be closely 
monitored and directed to achieve optimal firm performance.  
 
According to Gallaugher (2002), technological systems in the firm’s supply chain can be broadly 
classified in three categories; Complex technological business systems, such as ERP (Enterprise 
Resource Planning) systems which are designed to cover and connect the entire company’s 
operations. Focused technological solutions which comprise of the lower level of technological 
solutions that facilitate the optimization of certain business functions or that improve visibility 
along the channels and include Warehouse Management System (WMS), Advanced Planning 
System (APS) or Transport Management System (TMS) and technological tools that offer 
managerial solutions: such as Radio Frequency Identification (RFID), Electronic Data 
Interchange (or EDI) or the Internet.  
 
In a desk review of the application of technology in the pharmaceutical supply chain in Europe, 
Vivarelli (2015) found that technological innovations deployed in the pharmaceutical industry in 
Europe had led to may be direct labor saving through increased efficiency and productivity with 
the most notable changes noted in the supply chain of drugs and other pharmaceutical products. 
It was noted that by adopting technology especially downstream, organizations were able to 
avoid any stock-outs or carriage of dead inventory since intelligent supply management software 
was able to effectively predict demand and ensure availability of inventory just in time. Product 
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flows from producers through wholesalers to retailers and ultimately the final buyer largely 
depends on systematic, strategic planning by a firm and sound management.  
 
It was also noted that the immense potential inherent in automation of pharmaceutical supply 
chains especially linkage of distributors and parent company through electronic platforms that 
would provide updated demand data. This he opined had the potential to increase efficiency in 
the industry by up to 25% which he predicted would reflect directly on the balance sheet of 
concerned firms. The study however failed to factor other aspects of technology within the 
pharmaceutical industry and this gap is addressed by the current study. Further, being done in 
Europe meant its contextual realities may differ from those of the current study that will be done 
on pharmaceutical firms in Kenya.  
 
In Africa, supply chain for pharmaceutical firms are not as robust as supply chains in developed 
countries. In a study on whether Africa should make its drugs, there are indications that sourcing 
pharmaceuticals products from other countries outside Africa lengthens the supply chain 
especially with regard to stringent trade polices (Conway, Holt & Sabow, 2018). In this study, 
there are recommendations that pharmaceutical firms should adopt technologies that will 
improve the supply chain operations where sourcing of the products can be done online. 
However, there are is no study that provides assessment on the extent to which the sourcing of 
pharmaceutical products has improved supply chain. This study therefore bridged this gap by 
investigating the effect of technology on supply chain.  
 
Munyasi (2015) notes that the key objective of use of technology in supply chain management is 
integration across the different players which he argued would deliver many positive effects. 
Basing on comprehensive information sharing that is more accurate and faster, firms can get 
better demand forecasts that are based on precise information. Technology if properly deployed, 
he argued, not only serves to facilitate this process but further integrates the entire system, so that 
the process flow for demand and supply complements continuously. A smooth process flow 
ensures efficiency and productivity at its optimal which reflects on the overall firm performance. 
By applying digital technology, companies can significantly increase visibility into their supply 
chain operations and make better and faster decisions. Digitization allows companies to fully 
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integrate their supply chains and improve operational processes, making them more adaptive and 
responsive. As a result, planning accuracy, manufacturing efficiency and productivity, inventory 
levels, and service levels improve.  
 
Jepkoech (2012) carried out a study on the effect of technology on supply chain performance 
using a case study of Postal Corporation of Kenya. The study noted that technology increased the 
agility of employees thereby improving the efficiency and effectiveness with which they 
completed tasks before them. The study further found that technology deployed in staff 
retraining improved the organizations reach to staff across the various stations and was key to 
enhancing service delivery. The study recommended the use of technology in demand projection 
to further reduce impediments to smooth flow of products and services within the firm’s supply 
chain. The study was however limited to a specific organization and was fairly general in its 
discussion of technology on supply chain performance. It also focused mainly on the employee 
effects and not on the primary focus of the current study i.e. operational performance. 
 
In another study, Munyasi (2015) examined the impact of technology adoption on 
pharmaceutical industry’s distribution in Kenya. It was found that pharmaceutical companies that 
embraced new technologies had a competitive edge in sourcing and distribution of drugs due to 
the reduction in the costs associated with transportation, coordination and storage of products. 
The study further found a reduction in delivery turnaround timelines, reduction in data entry 
errors and enhanced accuracy in reporting and communication all of which served to improve 
overall efficiency not just within the supply chain but in the overall firm performance. The study 
however only concentrated on retail outlets and not the main pharmaceutical companies that this 
study seeks to study. The study only concentrated on the distribution systems and no other 
aspects of technology within the pharmaceutical industry in Kenya, a gap that the present study 
intended to address.  
2.3.3 Marketing Technology and Operational Performance 
Marketing technology has been increasingly adopted to support organizations reach out to more 
markets or consumers. According to Ngamau (2016), for businesses to remain viable, 
pharmaceutical firms will need to alter the marketing that focuses only on the product of the 
current model and create new strategies that recognize the importance and interdependence of 
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the payer, provider. This would underscore the pharmaceutical value chains thus providing a 
win-win situation for all interested parties benefiting from the complex and interactive processes 
within the chain. While there is steady demand for pharmaceutical products, the dynamics in the 
industry are so diverse and are constantly reshaping the marketplace. The demand for medicines 
is projected to grow rapidly over the coming years with governments focusing more on 
prevention rather than treatment; regulators are becoming more risk-averse and consumers better 
informed.  
 
Rasmussen (2010) observed that key market segment for pharmaceutical companies has been the 
physician employed by the pharmaceutical firms. This aims at meetings between physicians and 
sales representatives to explain the advantages of a particular medication. Each new drug has 
been launched with a comprehensive and expensive global marketing campaign that involved the 
full range of marketing tools including media advertising, comprehensive information packs. 
These culminate into special events for doctors, conference presentations, and a dedicated sales 
force in this new model of partner firms. Increased investment in marketing and firm specific 
experience (Kor & Mahoney, 2005) also helps in building capability. However, the marketing 
budgets for most firms have progressively increased with the WHO (2016) attributing the high 
cost of medicines to the competitive nature of the industry that necessitates huge investments in 
marketing. Contemporary consumers are more educated, better informed, more technology 
savvy, have more purchasing power and hence, more demanding in the products and services 
they buy (Kotler & Keller, 2006).   
 
Khedkar (2015) examined the effect of social media on customer satisfaction and loyalty in 
Indian pharmaceutical organizations. The study found that social media was increasingly 
becoming the marketing tool of choice for many companies across India since the customer 
‘finds you.’ The study also found an increasingly important role played by consumers especially 
on social media platforms that was forcing many companies to improve their products and 
services since consumers were readily sharing both positive and negative experiences. The study 
recommended increased investment in social media as a marketing tool for any firm that sought 
to operate sustainably since it was proving to be an ever increasingly important marketing tool 
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that required great innovation but could hinge on technology and become very effective without 
being too expensive.  
 
The study however was mainly empirical in nature as opposed to the current study that will 
employ both a theoretical framework as well as empirical research. Its societal and geographical 
context are distinctly different from Kenya as is the pharmaceutical industry in both countries, 
this could have a bearing on the findings of the current study.  In Nigeria, Melodi, Olufayo and 
Gbadamosi (2012) conducted an appraisal of marketing technology in the banking sector using a 
study of four selected banks in Lagos State. They found that marketing technology had 
significant and positive impact on income generation capacity and profitability level of the 
studied banks. It not only increased their visibility but created interactive platforms for the banks 
to respond to customer needs faster. Their subsector of study was the banks which differ 
markedly with pharmaceutical industry and thus the current study will seek to find out whether 
the same applies in its subsector of interest. 
 
Ndubai (2013), studied competitive marketing strategies in the retail sector of the pharmaceutical 
industry in Nairobi and found that strategies used included strategic choice of location, stocking 
other items like cosmetics, surgical and diagnostic items, attractive counter displays, staff 
uniforms and road signboards. His study projected that technology would increasingly become 
significant in the marketing of pharmaceuticals and he recommended that for a retail outlet to 
remain, viable, they would need to employ some form of technology in their marketing. The 
study however failed to focus on the projected operational gains that would come from 
embracing technology. It was also done on retail outlets and its findings though relevant may not 
fully apply to the parent firms under this study. 
 
Ngumau (2016) studied the challenges facing the marketing of pharmaceutical products in Kenya 
and found that the pharmaceutical distribution companies have to deal with the lack of adequate 
product knowledge from the customers and their clients which make them vulnerable to 
counterfeits and grey medicines. The study also found that many distribution companies 
complained of underfunding from parent pharmaceutical firms in promotional activities. 
Regulatory hindrances were also noted with many distributors noting the strong regulatory 
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framework in drug promotion activities. The study however failed to address technology 
specifically as a marketing tool or its potential effects. The study focused only on distribution 
companies and not the parent pharmaceutical firms whose products the distributors push. The 
study also failed to address operational performance which is the key variable of the present 
study.  
2.3.4 Quality Control Technology and Operational Performance 
As part of a maturing industry, pharmaceutical companies are under significant pressure to both 
innovate and successfully manage increasingly complex operations, more stringent regulatory 
requirements and frequent consolidations (Guzman, 2010). Many are rethinking their Quality 
Management Systems (QMS), recognizing the imperatives to enhance agility and improve 
responsiveness to market needs without increasing quality-related costs or ultimately 
compromising product quality. While the benefits are clear, a misalignment between the QMS 
and a company’s operational requirements can have downsides and drive costs. WHO (2016) 
notes that a lean and agile QMS will be a key source of competitive advantage if it has the ability 
to capture customer feedback and regulatory changes, build them into operations and rapidly 
launch new products to market. It should also offer a streamlined structure that enables both 
compliance and operational efficiency, even when faced with increased business complexity.  
Recent pharma industry trends have had significant implications on the need for robust quality 
control. Technology advances have for example increased the diversity of products and 
processes. Products may have more elements (for example, the drug itself, software and a 
device), while traditional product lines (small and large molecules) have matured and new 
processes are increasingly more complex all of which has served to increase the need for greater 
prudence to ensure quality maintenance (Woodcock, 2010). Regulators are using technology to 
gain access to data and tools that enable more frequent and more in-depth audits with an end-to-
end scope. This increased scrutiny demands more extensive sharing of information and a greater 
emphasis on its integrity. At the same time, advanced analytics are greatly enhancing the ability 




With emerging challenges like counterfeits and parallel imports, there is need to track batches, 
monitors temperatures to ensure stability of product and efficacy right to the end user. 
Traditionally, pharmaceutical companies have focused on the combination of approaches for 
quality control approaches. However, quality control is increasingly emerging as an important 
aspect of the industry and involves a broader platform to ensure quality by “bottom-up” 
approach. Larson, (2006) posits that ‘Quality by Design’ (QBD) is a customized and a latest 
version of quality management system in pharma sector. It covers “QBD” of pharma products by 
designing, development of formulation and various manufacturing processes to predefined 
product quality. Overall, a quality management system ensures that the products that reach the 
consumer are safe, efficacious & of high quality.  
Regulatory Affairs falls squarely under quality control and plays a crucial role in the 
pharmaceutical industry and is involved in all stages of drug development and after drug 
approval and marketing. Malik (2016) notes that the drug development process is a lengthy, 
complex and extremely costly albeit necessary process. Pharmaceutical companies use all the 
data accumulated during discovery and development stages in order to register the drug and thus 
market the drug. Throughout the development stages, pharmaceutical companies must abide by 
an array of strict rules and guidelines in order to ensure safety and efficacy of the drug in 
humans. In this highly regulated environment, regulatory affairs play a critical role not only as 
the interface with health agencies and as a link between different departments in the company 
but also as the leading department to provide strategic advice on extremely difficult decisions 
through the life of a drug (WHO, 2013). Technology has proven a great asset in this endeavor 
and has been pivotal in the improvement of process efficiency and resource optimization.   
Sigei (2014) studied total control and performance of multinational pharmaceutical firms in 
Nairobi and found a positive correlation between quality control standards and firm’s 
performance. The study also found a positive relationship between the use of technology in 
quality control and overall efficacy of products. The study also identified the role technology in 
staff training on advanced quality control and recommended its use to make training more 
efficient and economical.  The study however failed to address technology as a key variable in 
quality control a gap the present study seeks to bridge. The study also concentrated on 
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multinational firms and failed to consider the local firms thus probably failing to capture certain 
relevant aspects.  
Kiragu (2014), studied government regulation and firm competitiveness in insurance and found 
that the government regulations affect the competitiveness in many ways and this is especially 
significant in life companies where return on investment have big impact on profitability and 
fund growth, thus requiring greater capital investment is restricting entry of firms while at the 
same time encouraging mergers and buyouts. It was noted on the study that technology was 
being successfully deployed to enforce the regulatory framework and this had a direct 
consequence of quality control on products. The study however focused on the insurance 
industry and not in pharmaceuticals. It also focused more on overall returns without giving much 
thought to operational efficiency which is a main focus of the current study.  
In another 2014 study, Mutua studying quality management practices and financial performance 
of pharmaceuticals manufacturing firms in Kenya found that most pharmaceutical manufacturing 
firms that implemented technology backed quality management practices recorded high sales 
turnover leading to organizational performance. The study recommended that pharmaceutical 
manufacturing firms in Kenya should benchmark themselves with the best performing firms 
globally in order to map the quality management technology they deployed to improve overall 
performance. It however only concentrated on quality management practices in general with 
specific technological applications without regard for the deployment of technology in other 
spheres of the firm as done by the present study.  
2.4 Chapter Summary and Knowledge Gaps  
The reviewed studies generally indicate that technology continues to be a major determinant in 
improving operational performance of pharmaceutical firms. In developed countries, technology 
in pharmaceutical firms is used in research and development (Boldeanu and Pugna, 2012). Also, 
technology is used in monitoring safety of patients with regard to use of drugs (Abdolvand, 
Albadvi and Ferdowsi, 2012). In addition, technology is used to allow patients get control of 
their health by consulting pharmaceutical firms (Porter, 2010). However, while developing 
countries are in increasingly adopting technologies, the intentions of using technologies remains 
largely unexplored. For example, in Kenya while there is online provision of pharmaceutical 
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services, the extent to which such platforms support operational performance remains 
undetermined.  
On supply chain and operational performance, the reviewed literature indicates that use of 
technology by pharmaceutical firms in developed countries increased efficiency and productivity 
of the firm. In Europe, use technology improved supply chain efficiency in the industry by up to 
25% (Vivarelli, 2015). However, the study failed to factor other aspects of technology within the 
pharmaceutical industry and this gap is addressed by the current study. Comparatively, 
developing countries do not have robust supply chain of pharmaceutical firms and therefore 
recommendations for the firms to adopt technologies have been put in place (Conway, Holt & 
Sabow, 2018). However, the extent to which the sourcing of pharmaceutical products has 
improved supply chain has not been investigated. In other studies, while it was established that 
technologies improved supply chain, the studies did not focus on pharmaceutical firms 
(Jepkoech, 2012); focused on retail outlets and not main pharmaceutical manufacturers or 
packagers. This study therefore bridged this gap by investigating the effect of technology on 
supply chain with regard to main pharmaceutical manufacturers or packagers.  
On marketing technology and operational performance, reviewed studies indicate that 
technologies are widely used in marketing in many countries across the world. For example, in 
India technology supports introducing pharmaceutical products to large population (Khedkar, 
2015). In Kenya, there are limited studies on the extent to which technology supports 
pharmaceutical firms in marketing. For example, study by Ngumau (2016) failed to address 
technology specifically as a marketing tool or its potential effects. Thus, this study determined 
the extent to which technology affects marketing with regard to pharmaceutical firms. 
On quality control technology and operational performance, the reviewed studies indicate that 
there are inadequate studies in Africa with regard to quality control in pharmaceutical firms 
through technology. The a few studies (Sigei, 2014; Mutua 2014) fail to address technology as a 
key variable in quality control. It is against this backdrop in lack of empirical evidence on 





2.5 Conceptual Framework 
Figure 2.1 describes the conceptual framework of this study.  
Independent Variable  
Technology   
 
                                                                                                                Dependent Variable  











Figure 2. 1: Conceptual framework 
Source: Researcher (2019) 
The conceptual framework describes the relationship between independent and dependent 
variables. The independent variables are supply chain, marketing technology and quality control 
technology. The indicators for supply chain technology are distributor tools, inventory tools and 
internal integration tools. The indicators for marketing technology are webinars, social media 
and market segmentation tools. The indicators for quality control technology include digital drug 
registry, digital licensing renewals and portable temperature packs. The dependent variable is 
operational performance of the pharmaceutical firms. The indicators are control, quality, time 
and flexibility. The relationship indicates that increased positive influence of technology (supply 
chain, marketing and quality) increases operational performance of the pharmaceutical firms. 
The relationship also indicates that in case of negative influence in technology (supply chain, 
marketing and quality) decreases operational performance of the pharmaceutical firms.  
Supply chain technology  
• Distributor RM tools,  
• Inventory MS tools,  
• Internal integration tools 
(ICT) 
Performance 
• Control  
• Quality  
• Time  
• Flexibility  
 
Marketing technology 
• Webinars,  
• Social media,  
• Market segmentation tools 
Quality control technology 
• Digital drug registry,  
• Digital licensing renewals, 




2.6 Operationalization of Variables 
The Table below describes the operationalization of variables. The Table illustrates operational 
definition of the study variables and how the variables will be measured. The supporting 
literature for each variable is also provided. 
Table 2. 1: Operationalization of Variables 









Supply chain technology is 
automated logistical arrangement 
of pharmaceutical services 
supporting manufacturers, 
distributors, retailers and 
consumers.  
• Distributor 
RM tools,  











Marketing technology is a set of 
automated processes and tools 
used by pharmaceutical firms to 
increase visibility of the firm as a 
brand in the market or products 
and services sold.  
• Webinars,  
















Quality technology refers to set of 
automated tools and processes 
used by regulatory bodies and 
pharmaceutical firms to enforce 
standards and ensure compliance.  
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technology refers to level of 
efficiency and effectiveness in 
pharmaceutical firms.  
• Control  
• Quality  
• Time  

















This chapter presents the methodological approach that will be used for the study and 
specifically discusses the intended research design, target population, data collection procedure, 
data analysis procedure, reliability and validity of the instruments as well as addressing the 
ethical considerations that may arise from this study.  
3.2 Research Design 
The study adopted cross-sectional survey design to determine the influence of technology on 
operational performance of pharmaceutical firms in Kenya. This design ascertains and describes 
the characteristics of the variables of interest in a situation at a specific point in time (Kerlinger, 
2000). Cross-sectional survey design is restricted to a fact finding and may result in the 
formation of important principle of knowledge and solutions to significant problems (Kothari, 
2004). Similarly, it involves collection of data from large area by use of questionnaires to 
determine characteristics within the population (Kreswell, 2003). Thus, cross-sectional research 
design therefore supported identification of respondents by use of census and purposive random 
sampling technique as well as use of inferential data analysis.  
3.3 Target Population 
A population refers to an entire group of individuals, events or objects having a common 
observable characteristic about which a researcher is interested in (Sekaran, 2008). It describes 
the parameters whose characteristics the research will attempt to describe. It comprises of all 
potential participants that can make up the study group (Kumar, 2008). Kenya has 50 registered 
pharmaceutical manufacturing and distributing firms (Pharmacy and Poisons Board, 2019). Four 
managers in every firm. These managers were selected based on their areas, supply chain 
manager, marketing manager, quality control manager and the operation manager in each firm 
selected to form part of the target population giving us a total target respondents of 200.  
 3.4 Sample size and Sampling procedure 
The study aimed to achieve a 95% confidence level and 5% margin of error. Given the small 
population of 50 firms, a census approach was adopted targeting all of the firms.  
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3.5 Data Collection Procedure 
Primary data was collected from sample management executives in pharmaceutical firms in 
Kenya using questionnaires constructed in a five-point Likert scale. The questionnaires were 
administered through drop and pick up later method, and the data was collected within a period 
of one month. The questionnaire comprised of structured questions, made up of five sections 
namely section A: comprised of the demographic information, section B: Level of technology 
Section C: Supply Chain Technology, section D: marketing technology E: quality control 
technology F: operational performance. One research assistant was engaged in the data 
collection. The research assistant was given a brief orientation on the aim and objective of the 
study, the targeted population, sample and sampling procedure as well as the ethical issues in the 
study.  
3.6 Research Quality 
The quality of this study was guaranteed by testing validity and reliability of the questionnaire as 
follows: 
3.6.1 Validity 
Validity determines whether the research truly measures that which it was intended to measure or 
how truthful the research results are (Joppe, 2000). Content validity was determined using the 
expert advice from my supervisors. A pilot test of five respondents randomly selected from the 
sample frame was done to test the reliability of the instrument. The five were then excluded from 
the final respondents to avoid contamination.  
3.6.2 Reliability  
Reliability is the extent to which an instrument is predictable, stable, accurate and dependable to 
yield the same results every time it is administered. Reliability demonstrates that the study can be 
replicated. The study used a test retest for reliability which was then verified using Cronbach’s 
alpha with a threshold of 0.7 to determine its reliability. 10 percent of the target population was 
used to conduct pilot test but these were managers who were from similar firms but were not to 
participate in the study like finance managers, credit management division unit and the directors 




Table 3. 1:Reliability coefficient of variables 
Variable  No of items  Respondents  Alpha  Comment  
Operation 
performance  
11 20 0.825 Reliable  
Level of 
technology  
6 20 0.741 Reliable  
Supply chain 
technology  
10 20 0.882 Reliable  
Marketing 
technology  
11 20 0.912 Reliable  
Quality control 
technology  
7 20 0.931 Reliable  
3.7 Data Analysis Procedures 
The collected research data was edited and cleaned then coded, categorized and lastly keyed into 
for final data processing. Data was analysed using computer supported software Statistical 
Package for Social Sciences (SPSS). Means were obtained for each variable and regression 
analysis was done to provide correlation coefficients for determination of the influence of the 
technology on operational performance.  
Table 3. 2:Data Analysis Procedure 
Objective Measurement Indicators  Data analysis procedure 
RO1. To establish level 
of technologies used by 
pharmaceutical firms in 
Kenya 
Number of automated 
pharmaceutical processes and 
number of interphases.  
Quantitative data of number of 
processes and interphases was coded, 
entered on SPSS, tabulated and 
expressed in form of means. 
 
RO2. To assess the 
influence of supply 
chain technology on 
operational 
performance of 
pharmaceutical firms in 
Kenya 
Distributor relationship 
management tools, Inventory 
management tools, Internal 
integration tools 
Quantitative data on distributor 
relationship, management tools, 
inventory management tools and 
internal integration tools will be 
coded, entered on SPSS, tabulated and 
expressed in form of means.   
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Objective Measurement Indicators  Data analysis procedure 
RO3. To determine the 
influence of marketing 
technology on the 
operational 
performance of 
pharmaceutical firms in 
Kenya 
Webinars, social media, 
Market segmentation tools,  
Quantitative data on webinars, social 
media and market segmentation tools 
will be coded, entered on SPSS, 
tabulated and expressed in form of 
means.   
RO4. To assess the 
influence of quality 
control technology on 
the operational 
performance of 
pharmaceutical firms in 
Kenya 
Digital drug registry, digital 
licensing renewals, portable 
temperature packs 
Quantitative data on digital drug 
registry, digital licensing renewals, 
portable temperature packs will be 
coded, entered into SPSS, tabulated 
and expressed in form of means.   
RO5. To establish the 
operational 
performance of 
pharmaceutical firms.  
Control, Quality,  
Time and Flexibility  
Quantitative data on control, quality,  
time and flexibility will be coded, 
entered into SPSS, tabulated and 
expressed in form of means.   
RO6 To determine joint 
influence of supply 





pharmaceutical firms in 
Kenya 
 The means obtained on performance 
of pharmaceutical firms will be 
compared with means on supply 
chain, marketing and quality control. 
The comparison on means will yield 
Pearson correlation coefficients. Also, 
regression analysis will be done to 
obtain regression coefficient of 
independent variables (supply chain, 
marketing and quality control) 
regarding operational performance of 
pharmaceutical firms in Kenya.  
 
A regression model was generated showing operational efficiency and technology. The 
regression coefficients were assessed for statistical significance. The relationship between 
operational performance and technology was expected to follow a regression model of the nature 
below:  




Y= Operational performance 
α = Intercept term  
X1=Supply chain technology  
X2= Marketing technology  
X3= Quality control technology 
ε= Error term  
3.8 Ethical Consideration 
Ethical consideration involved obtaining permission to conduct the study from institutions and 
respondents as well using polite language. On approval, permission letters from Strathmore 
University was obtained. The letter was used to obtain research permit from National Council of 
Science, Technology and Innovation (NACOSTI). Permission letter from the University and 
research permit were used to obtain permission from pharmaceutical firms in Nairobi. 
Respondents were also politely requested to participate in the study. According to Mugenda 
(2003), an ethical study is one that allows for freedom of purpose from the participant as well as 
protects their rights. This involved provision of a clause in the introduction section of the 
questionnaire that allowed respondents to willingly participate in the study or not. According to 
Creswell (2014), respondents should be informed of the nature and procedures of the study to 
allow the researcher to get consent. In this regard, the researcher ensured the confidentiality and 
anonymity of the participants by use of pseudonyms in the data gathered. After the completion of 
administration of questionnaires, respondents were given opportunity to review their responses 
and to make any changes to their previous statements.  
The researcher also ensured ethical consideration by acknowledging authors and contributions of 
all literature used in the study. Respondents were not to be identified by their respective names 
and they were allowed to participate in the study voluntarily. Throughout all processes of data 
collection, objectivity was maintained where there was no misinterpretation of information. In 
addition, data collected was used for academic purposes only. Analysed data was only applied in 





DATA ANALYSIS AND INTERPRETATION OF FINDINGS 
4.1 Introduction  
This chapter presents findings from the data analysis in line with the research objectives. The 
analysis is divided into four sections. Section 4.2 is the response rate, section 4.3 presents the 
background information and section 4.4 presents the analysis as per the research objectives. 
Section 4.5 presents the inferential statistics. 
4.2 Response Rate 
A population of 50 pharmaceutical firms was obtained and 200 questionnaires administered to 50 
Operations Managers, Supply Chain Managers, Marketing Managers and Quality control 
Managers. However, only 178 questionnaires were successfully filled and returned representing 
89% success rate in 45 pharmaceutical firms. The response rate was considered adequate for data 
analysis.  
4.3 Background Information 
The background information collected was on type of pharmaceutical firm, years in operation 
and firm’s major functions. The findings are illustrated and presented as follows: 
4.3.1 Respondents type  
Analysis of respondents who participated in the study show that out of targeted 200 , only 178 
completely filled the questionnaires and returned and that was what was used to develop the 
analysis. The results showed in table 4.1 
Table 4. 1:Respondents Response Rate   
 Frequency Actual Response  Percentage 
Operation managers 50                43 86% 
Supply chain managers  50 45 90% 
Marketing manager  50 44 88% 
Quality control manager  50 46 92% 
Total  200 178 89% 
The findings in Table 4.1 shows response rate among the managers who participated in the 
study. Majority of responses were received from quality control managers (92%), supply chain 
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managers 90%, marketing managers 88% and operation managers had response rate of 86%. 
Overall response rate was 89%, with only 11% not responding to the study questionnaire 
distributed.  
4.3.2 Period in the company  
Respondents were requested to indicate the period in which the firms have been in operation. 
The findings are illustrated in Table 4.2.  
Table 4. 2: Years of Experience at the company 
Years of Experience Frequency Percentage 
4.1-8.0 years 33 18.5 
8.1-12.0 years 70 39.3 
Above 12 years 75 42.1 
Total  178 100.0 
Findings in Table 4.2 indicate that more managers (42.1%) have operated has stayed in firms for 
more than 12 years followed by those who had worked in their respective pharmaceutical firms 
between 8 years to 12 years were 39.3 percent and 4 to 8 years were 18.5 percent. The findings 
indicate that before a person promoted to management position years of experience and stability 
of having worked in the same firm was found to be a significant determinant.  
4.3.3 Major Functions of the Firms 
Respondents were requested to indicate the major functions of the firms. The findings indicated 
that all firms (100%) engaged in manufacturing, distribution, customer care, marketing, quality 
control and advocacy. The firms manufactured and distributed human and livestock drugs. The 
distribution was supported by robust marketing strategies. In addition, the firms invested and 
complied with standards that ensured quality in the operations. Also, the firms engaged in forms 
of advocacy including promotion of safe usage of drugs and favourable legislation on 
pharmaceutical legal frameworks. The findings imply that pharmaceutical firms in Kenya engage 
in multiple activities that utilise technology in one form or another.  
4.4 Operational Performance 
This section presents findings on operation performance of pharmaceutical firms. There were 
five items used for testing operational performance variable on a five Likert scale. The scale 
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ranged from strongly agree (5), Agree (4), undecided (3), disagree (2) and strongly disagree (1). 
The findings are illustrated in Table 4.3 
 















There is increased timely delivery of 
products to customers. 
0 21.9 16.9 23.0 40.2 3.29 1.189 
There is increased level of obtaining 
customer compliments and complaints. 
0 22.5 21.3 16.9 39.3 3.25 1.216 
There is reduced costs of supply chain 
operations. 
0 21.3 21.3 16.9 40.4 3.25 1.157 
There is improved product awareness for 
customers in the market 
0 23.6 17.4 18.5 40.4 3.22 1.191 
There is reduced costs of marketing 
activities. 
0 17.4 24.2 16.9 41.6 3.20 1.156 
There is improved time of serving 
customers 
0 21.9 20.8 14.0 43.3 3.19 1.183 
There is increased the firm’s ability to 
respond to customer/ market demands 
0 19.7 21.9 19.7 38.8 3.17 1.186 
There is improved satisfaction level of 
customers. 
0 20.8 23.0 19.7 36.5 3.16 1.109 
Any other (improved research) 0 19.1 14.6 22.3 43.8 3.16 1.104 
There is increase in revenues resulting 
from marketing activities 
0 16.3 24.2 21.3 38.2 3.15 1.198 
There is increased level of responding to 
customer compliments and complaints. 
0 15.7 21.9 18.0 44.4 3.10 1.130 
The firm has ability to meet regulatory 
demands 
0 13.5 20.2 19.1 47.2 3.05 1.121 
There is improved overall product and 
service quality offering by introducing 
global standards. 
0 15.2 21.9 24.2 38.8 2.99 1.100 
Overall Mean      3.17 1.157 
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Findings in Table 4.3 indicate that high operational performance of the pharmaceutical firms is 
observed in timely delivery of products to customers (mean of 3.29). Least performance is 
observed in introduction of global standards (mean of 2.99). The findings imply that with an 
overall mean of 3.17, pharmaceutical firms have high performance resulting from supply chain, 
marketing and quality control activities. Overall mean of 3.17 also implies that the 
pharmaceutical firms have technologies that help in undertaking supply chain, marketing and 
quality control operations.  
4.5 Levels of Technology Used 
This section presents findings of the first objective of the study. The section presents findings on 
level of technology used by pharmaceutical firms in Kenya. There were five items used for 
testing Levels of Technology variable on a five Likert scale. The scale ranged from strongly 
agree (5), Agree (4), undecided (3), disagree (2) and strongly disagree (1). The findings are 
illustrated in Table 4.4 
Table 4. 4: Levels of Technology Used 
Statement 1  
(%) 












Firms use technology in making orders. 0 0 0 52.2 47.8 4.48 .501 
Firms use technology in marketing 0 35.4 13.5 21.9 29.2 3.49 .970 
Firms use technology in making sales 
(taking customer requests, payment and 
dispensing drugs). 
0 18.0 30.9 34.8 16.3 3.45 1.244 
Firms use technology in managing 
inventories. 
0 38.2 21.3 20.8 19.7 3.41 1.152 
Firms use technology in advising 
members of the public and customers on 
drugs and usage. 
0 29.8 23.6 22.5 24.2 3.22 1.156 




Overall mean      3.54 1.036 
Findings in Table 4.4 indicate that pharmaceutical firms in Kenya use technology for various 
activities. Technology is most used in making orders (mean of 4.48) followed by marketing 
(mean of 3.49) and making sales (mean of 3.45). The least use of technology is in general 
planning, analysis and reporting (mean of 3.16). From the overall mean of 3.33, the level of 
technology was considered high. The values on the Likert scale above 2.5 represented high level 
of technology while mean values of below 2.5 represented low use of technology. The findings 
indicate that pharmaceutical firms in Kenya use technology highly in their operations mainly 
supply chain, marketing and quality control.  
4.6 Supply Chain Technology and Operational Performance 
This section presents findings on supply chain technology that supported the second objective on 
the influence of supply chain technology on the operational performance of pharmaceutical firms 
in Kenya. The findings are illustrated as follows: 
4.6.1 Supply Chain Technology 
There were five items used for testing Levels of Technology variable on a five Likert scale. The 
scale ranged from strongly agree (5), Agree (4), undecided (3), disagree (2) and strongly disagree 















Table 4. 5: Supply Chain Technology 
Statement 1 
(%) 












Firms share information with suppliers 
through the electronic network 
0 24.2 18.0 16.3 41.6 3.46 1.189 
Firms use an MRP system (to harmonize 
forecasting, procurement, production and 
sales) 
0 25.8 15.7 26.4 32.0 3.25 1.162 
Firms use technology to ensure product 
availability JIT 
0 20.8 20.8 19.7 38.8 3.24 1.160 
Firms use technology in planning and 
developing supply chain needs 
0 21.3 23.6 18.5 36.5 3.23 1.225 
Firms and suppliers relate to an electronic 
system to control inventory 
0 17.4 15.2 19.7 47.8 3.22 1.172 
Others (supply chain reporting) 0 18.5 23.6 14.1 38.8 3.22 1.156 
Distributors profiles are used in their 
relationship management 
0 21.3 24.7 17.4 36.5 3.17 1.139 
Firms employ technology to collect 
customer feedback to improve its supply 
chain. 
0 20.2 20.8 18.0 41.0 3.17 1.173 
Firms’ internal departments are 
electronically interconnected 
0 16.3 18.5 18.0 47.2 3.07 1.172 
Firms employ technology to collect 
customer feedback to improve products. 
0 19.1 19.7 22.5 38.8 3.03 1.144 
Overall mean      3.206 1.169 
Findings in Table 4.5 indicate that pharmaceutical firms are using technology to perform supply 
chain activities. With mean of 3.46, the firms share information regarding supplies on electronic 
network that include emails. Also, with mean of 3.25, the firms use MRP systems to harmonise 
forecasting, procurement, production and sales. With an overall mean of 3.21, the findings imply 
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that technology was intensively used in all stages of supply chain mainly planning, 
implementation and reporting.  
4.7 Marketing Technology and Operation Performance 
This section presents findings of objective 3 on influence of marketing technology on the 
operational performance of pharmaceutical firms in Kenya as follows: 
4.7.1 Marketing Technology 
There were five items used for testing Levels of Technology variable on a five Likert scale. The 
scale ranged from strongly agree (5), Agree (4), undecided (3), disagree (2) and strongly disagree 
























Table 4. 6: Marketing Technology 
Statement 1  
(%) 












Firms use social media (Facebook, 
Twitter and You Tube) to actively market 
its products 
0 34.3 19.1 24.7 21.9 3.34 1.165 
Others (research) 0 33.7 24.7 23.0 18.5 3.33 1.172 
Social media is used to create market 
awareness about new products. 
0 40.4 19.1 18.0 22.5 3.30 1.167 
Firms use technology to articulate its 
unique selling perspective (USP) 
0 37.6 14.6 28.1 19.7 3.29 1.189 
Technology has reduced the firm’s 
marketing budget 
0 43.8 20.8 16.9 18.5 3.26 1.116 
Firms use social media to receive 
customer feedback about a product. 
0 39.9 21.3 15.2 23.6 3.22 1.200 
Firms use webinars and e-conferencing to 
capacitate physicians 
0 46.1 17.4 15.2 21.3 3.22 1.205 
Firm use technology to segment the 
consumer markets 
0 43.3 18.0 13.5 25.3 3.21 1.243 
Firms monitor the market using 
technology 
0 38.8 24.7 15.2 21.3 3.19 1.168 
Firms anchor on technology to support its 
exposes 
0 36.0 23.6 16.3 24.2 3.12 1.209 
Firms have data base of relevant 
physicians for its product portfolio 
0 36.0 16.9 25.8 21.3 3.10 1.160 
Overall mean      3.23 1.181 
The findings in Table 4.10 indicate that marketing technology is used to increase brand image on 
social media platforms (mean 3.34), research (mean of 3.33) and market awareness (mean of 
3.30). Other uses of technology in marketing include monitoring and reporting. With an overall 
mean of 3.23, the findings imply that technology is highly utilised in marketing operations. The 
operations are both internal (planning and control) and external (interactions with consumers).  
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4.8 Quality Control Technology and Operational Performance 
In this section, findings on quality control technology and its influence on operation performance 
were presented with regard to objective 4.  
4.8.1 Quality Control Technology 
The findings on quality control technology are presented in Table 4.15 as follows: 
There were five items used for testing Levels of Technology variable on a five Likert scale. The 
scale ranged from strongly agree (5), Agree (4), undecided (3), disagree (2) and strongly disagree 
(1). The findings are illustrated in Table 4.4 
Table 4. 7:Quality Control Technology 
Statement 1  
(%) 












Firms have automated its drug registry 0 38.8 18.0 21.3 21.9 3.26 1.190 
Firms train staff and agents on latest 
industry innovations and trends 
0 39.9 19.1 21.9 19.1 3.21 1.182 
Firms have control tracking system to 
keep the inventory valid 
0 41.0 17.4 21.3 20.2 3.20 1.161 
Firms use technology to maintain just in 
time responses from end users 
0 43.3 20.8 16.3 19.7 3.17 1.154 
Firms rely on technology for testing of 
new molecules 
0 41.0 20.2 26.8 18.0 3.16 1.149 
Firms anchor on technology to meet its 
regulatory mandate 
0 41.6 16.9 24.2 17.4 3.12 1.172 
Any other (reporting) 0 41.6 24.6 14.6 19.1 3.11 1.149 
Overall mean      3.18 1.165 
Findings in Table 4.15 indicate that pharmaceutical firms are utilising quality control technology 
for various activities. The most utilised activities are automation of drug registry (mean of 3.26), 
followed by training (mean of 3.21), tracking of inventories (mean of 3.20), testing (mean of 
3.16). Other quality control activities in which technology is used include fulfilment of 
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regulatory technology (mean of 3.12) and reporting (mean of 3.11). With an overall mean of 
3.18, the findings imply that technology supports quality control activities. The findings also 
indicate that the pharmaceutical firms derive benefits from using technology in quality control 
operations. 
4.9 Tests for Model Assumptions  
Use of inferential parametric tests statistics procedures requires that the assumptions of such 
test’s normality, homoscedastity test, multicollinearity tests done  
4.9.1 Linearity Test 
Linearity test was done to determine whether relationship between independent variables (supply 
chain technology, marketing technology and quality control technology) and dependent variable 
(operation performance) are linear or not. The findings are illustrated in Table 4.21.    
Table 4. 8:Linearity Test 











(Combined) 1.587 17 .093 1.101 .357 
Linearity .000 1 .000 .002 .966 
Deviation from 
Linearity 
1.587 16 .099 1.169 .298 
Within Groups 13.570 160 .085   







(Combined) 1.621 19 .085 .996 .469 
Linearity .003 1 .003 .039 .844 
Deviation from 
Linearity 
1.617 18 .090 1.049 .409 
Within Groups 13.536 158 .086   







(Combined) 1.173 12 .098 1.153 .321 
Linearity .205 1 .205 2.422 .122 
Deviation from 
Linearity 
.968 11 .088 1.038 .415 
Within Groups 13.984 165 .085   
Total 15.157 177    
In linearity test, if values sig. Deviation from Linearity>0.05, the relationship between the 
independent and dependent variables are linearly dependent. The findings in Table 4.21 indicate 
that the Deviation from Linearity value of 0.298 for the relationship between supply chain 
technology and operation performance is >0.05. Also, the findings indicate that the Deviation 
from Linearity value of 0.409 for the relationship between marketing technology and operation 
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performance is >0.05. In addition, the findings indicate that the Deviation from Linearity value 
of 0.415 for the relationship between quality control technology and operation performance is 
>0.05. As the all the Deviation from Linearity values are >0.05, the findings imply that there is 
linear relationship between independent variables (supply chain technology, marketing 
technology and quality control technology) and dependent variable (operation performance). In 
this regard, any significant change in supply chain technology, marketing technology and quality 
control technology results into proportionate change in operation performance.  
4.9.2 Tests of Normality  
Normality tests according to Wheeler (2001) is useful since it helps to confirm whether the data 
follows a normal distribution. In cases where normality is violated, the results may fail to reflect 
a true picture of the relationship among the variables in the study. In this study normality was 
tested using Shapiro – Waik tests which is considered most appropriate for small samples < 500 
samples. In using this tests procedure, when significance value is less than 0.05 then the data 
significantly deviates from normality and therefore appropriate procedure to perform data 
transformation so as to observe normality must follow before running parametric tests statistics.  
The findings are illustrated in  
 Table 4. 9:Normality tests  
Variables  Shapiro – Wilk   
Statistics  df Sig. 
Supply technology 0.872 178 .267 
Marketing technology 0.711 178 .478 
Quality control technology 0.625 178 0.350 
a. Dependent Variable: Operation performance  
A Lililiefors Significance Correction  
The table shows that significance value for Shapiro- Wilk tests were 0.267 for supply 
technology, marketing technology 0.478 and 0.350 for quality control technology. Since p- 
values for Shapiro walk tests for all the variables were greater than 0.05 then we can accept null 
hypothesis that the data came from normally distributed population and therefore parametric tests 
statistics were considered ideal and therefore inferential statistics of persons correlations and 
multiple linear regression was considered permissible.  
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4.9.3 Multicollinearity Test 
Multicollinearity is a test that evaluates whether the independent variables are highly correlated. 
The primary concern is that as the degree of multicollinearity increases, the general regression 
model estimates of the model becomes unstable and the standard errors for the coefficients can 
get wildly inflated. Multicollinearity in this study was tested using Variance Inflation Factor 
(VIF). For the purpose of this study VIF less than 3 (VIF<3) means that no multicolliearity exists 
between the variables and (VIF> 3) means that there is multicollinearity which calls for 
correction before proceeding with testing for inferential tests statistics (Maddala & Lahiri, 1992).  
In the multicollinearity table, is shows that there was no multicollinearity among the independent 
variables since the VIF was less than the threshold of value 3.  
Table 4. 10: Multicollinearity Test 
Model 1 Collinearity Statisticsa 
Tolerance VIF 
Supply technology .742 1.500 
Marketing technology .721 2.494 
Quality control technology .799 1.301 
a. Dependent Variable: Operation performance 
The results showed that VIF for supply technology 1.5, marketing technology 2.494 and Quality 
control technology 1.301. There were no similarity between the independent variables with 
operational performance which would interfere with interpreting the model equation.  
4.9.4 Homoscedasticity Test 
Homoscedasticity is an assumption which is tested to confirm that variability of the variable is 
unequal across the range of values of a second variable which predicts it (Vinod, 2008). In this 
study homoscedasticity was tested using Breuch- Pagan/ Cook Weisberg test. For this test the 
null hypothesis is that the error variances are all equal while the alternative hypothesis is that the 
error variances are multiplicative function of one or more variables. In making decision whether 
a given population demonstrate homoscedasticity, p – values should be equal to or same as 0.05 
(Bera & Jarque, 2012). The results show that the constant variance (Chi2 = 12.12) is insignificant 
(p= 0.153). Thus, we fail to reject null hypothesis and conclude that the error variance is equal 
thus homescedasticity is evidence in the study data. In such a case, we therefore accept the null 
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hypothesis that there is no difference in residual variance of independent to dependent variables 
tested in the dataset.  
 Table 4. 11:Test for Homoscedasticity  
 HO Variables  Chi2 Pro. > Chi2 
Constant variance  X1 X2 X3  12.12 0.153 
 4.10 Inferential Statistics  
4.10.1 Correlation Results  
The results of the Pearson’s correlation coefficient indicate that there is significant positive 
correlation between supply chain technology, marketing technology, and quality control with 
operation performance. Correlation analysis was done to determine the strength of relationship 
between supply chain technology and operation performance, marketing technology and 
operation performance and quality control technology and operation performance.  










Supply Chain Tech 1  -  -  0.61* 
Sig.  
    0.00 
Marketing Tech  - 1  -  0.58* 
Sig    0.012 
 
Quality control tech  -  - 1 0.66* 
sig    0.000 
 
Operation Performance   0.61*  0.58*  0.66* 1 
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The results of Pearson’s correlation coefficient indicates that there is a significant positive 
correlation between supply chain technology, marketing technology and quality control 
technology and operation performance whereas (r = 0.61, p value < 0.05; a significant positive 
correlation between marketing technology with operation performance (r = 0.58* , p value is less 
than 0.05; and positive significant correlation between quality control technology and operation 
performance (r = 0.66* , p = 0.00). Overall, the study indicates that independent variable (supply 
chain technology, marketing technology and quality control technology) had positively 
moderately stronger association with dependent variables. This simply implies that any positive 
changes in supply chain technology, marketing technology and quality control technology would 
enhance operation performance of pharmaceutical industries.  
4.11 Simple Regression Results  
A simple regression analysis was performance in order to analyse the relationship between the 
three independent variables and the dependent variables. This was done by regressing the 
independent variables (supply chain technology, marketing technology and quality control 
technology) and operational performance. The regression results were organised on the basis of 
research question (hypothesis) of the study.   
4.11.1 To what extent has supply chain technology influenced operational performance of 
pharmaceutical firms in Kenya? 
Model Summary of Supply chain technology and operation performance 
Table 4. 13:Model Summary for Supply chain Technology  
Parameters  Coefficients 
Model  1 
R . 784a 
R Square .665 
Adjusted R Square 0.616 
Std. Error of the Estimate . 714 




The above R Square is 0.665 which means that 66.5 % variation in operation performance in 
pharmaceutical industries is caused by supply chain technology by 33.5% variability being 
caused by other factors which are not attributed to supply chain technology.  
 
Table 4. 14:ANOVA (Analysis of Variance) for Supply Chain Technology  
 Analysis of Variance 
Model Sum of Squares df Mean Square F Sig. 
Regression 265.53 1 265.53 441.35 .0.001b 
Residual 125.88 174 .585   
Total 391.41 177    
a. Predictors (constant), supply chain technology, dependent variable; operation performance  
Analysis of Variance (ANOVA) consists of calculations that provide information about the level 
of variability within the regression model and forms the basis for tests significance. The F 
column provides the basis for testing the hypothesis between the alternative and null hypothesis. 
From the table, the significance value is less than 0.05 thus indicating that the model is 
statistically significant in predicting how supply chain technology influence operation 
performance of pharmaceutical industries in Kenya.  
 Table 4. 15:Coefficient Results for Supply Chain Technology  





B Std. Error Beta 
(Constant) 4.313 0.518    9.03 .000 
Supply technology  0.65. 0.188 .502 3.925 .0025 
a. Dependent Variable: Operation performance 
 
Based on the regression results, holding Supply chain Technology constant at zero, operation 
performance of pharmaceutical firms would be 4.313. A unit increase in supply chain technology 
would lead to a 0.65 increase in operation performance of pharmaceutical firms in Kenya. At 5% 
significance level, supply chain technology had 0.0025 which is less than p< 0.05 and therefore it 
can be concluded that supply chain technology positively and significantly influences operation 
performance of pharmaceutical firms to a large extent.  
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4.11.2 To what extent does marketing technology influence the operational performance of 
pharmaceutical firms in Kenya? 
 Table 4. 16:Model Summary  
Model Summary for Marketing Technology  
Parameters  Coefficients 
Model  1 
R 0.58a 
R Square 0.336 
Adjusted R Square 0.378 
Std. Error of the Estimate 0.386 
a. Predictors: (Constant), marketing technology  
 
The value of R-Square is 0.336 which means that 33.6% variation in operation performance of 
pharmaceutical firms is due to the use of marketing technology with 66.4% being cause by other 
factors which is outside this model which is not marketing technology.  
 Table 4. 17:ANOVA (Analysis of Variance) for Marketing Technology   
Model Sum of Squares df Mean Square F Sig. 
Regression           365.90 1 365.9 481.35 .0.000a 
Residual 122.88     194   .585   
Total 488.78      195    
a. Predictors (constant), marketing technology, dependent variable; operation performance  
ANOVA comprise of calculations that provide information about the level of variability within a 
regression model and usually forms the basis for conducting tests of significance. The F column 
normally provides the basis for testing both null and alternative hypothesis of the variable. For 
instance, in the table the significance value is 0.000 which is less than 0.05 thus the model is 
statistically significant in predicting how marketing technology influences operation 








Table 4. 18:Coefficient Results for Marketing Technology  








(Constant) 4.709 0.814     5.03 .000 
Marketing technology ( 
X2) 
 0.719 0.411 
 
.642 4.925 .000 
 a. Dependent Variable: Operation performance 
 
Based on the regression results, holding marketing technology constant at Zero, operation 
performance of pharmaceutical firms would be 4.709. A positive unit change in marketing 
technology would lead to a 0.719 increase in operation performance of pharmaceutical firms in 
Kenya. At 5% confidence level, marketing technology had p= 0.000 which is less than 0.05 and 
hence the study can conclude that marketing technology positively and significantly affecting 
operation performance of pharmaceutical firms in Kenya to a great extent.  
4.11.2 To what extent has quality control technology influence the operational performance 
of pharmaceutical firms in Kenya? 
Table 4. 19:Model Summary for Quality Control Technology   
Parameters  Coefficients 
Model  1 
R 0.66.a 
R Square 0.4356 
Adjusted R Square 0.4451 
Std. Error of the Estimate 0.5251 
According to the table, the value for R-Square is 0.4356 which simply means that 43.56% of the 
variation in operation performance is due to variation in operation performance meaning that 
56.44% of the variation in operation performance of pharmaceutical firms is due to other factors 




Table 4. 20:ANOVA (Analysis of Variance) for Quality Control technology  
Model Sum of Squares df Mean Square F Sig. 
Regression           339.90 1 339.408 512.35 .0.000a 
Residual 180.88     274   .6625   
Total 520.78    275    
a. Predictors (constant), Quality Control   technology, dependent variable; operation 
performance  
 Analysis of Variance (ANOVA) consists of calculations that provide information about the 
levels of variability within the regression model and form a basis for tests of significance. The F 
column provides a statistic for testing hypothesis. From the findings, the significance value is 
0.000 which is less than 0.05 thus it can be deduced that the model is statistically significant in 
predicting how quality control technology influences operation performance of pharmaceutical 
firms in Kenya.   
Table 4. 21:Coefficient Results for Quality Control Technology   





B Std. Error Beta 
(Constant) 4.231 0.711    6.03 .000 
 
Quality Control Technology ( 
X3) 
      0.635 0.221 .647 2.925 .0025 
a. Dependent Variable: Operation performance 
Based on the regression results shown, holding quality control technology constant zero, 
operation performance of pharmaceutical firms in Kenya would be 4.231. A positive unit change 
in quality control technology would lead to 0.635 increase in operation performance. At 5% 
significance level, quality control technology had p= 0.0025 which is less than 0.05 and hence 
the study can deduce that quality control technology significantly and positively affects the 
operation performance of pharmaceutical firms in Kenya.  
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4.12 Overall Model  
A regression analysis of the overall model was performance. The results for the overall summary 
was presented. The study findings indicated that supply chain technology, marketing technology 
and quality control technology are positively associated with operation performance of 
pharmaceutical firms in Kenya as indicated by Person correlation R value of 0.909. 
Consequently, the proportion of the variance explained by R- Square which is 0.825. This simply 
means that 82.5% of operation performance is explained by combined effects of supply chain 
technology, marketing technology and quality control technology. From the ANOVA results the 
study confirmed the model fitness by comparing the F critical values where F value of 126.014 
which is significant at 0.000 which is less than 0.05. This shows that the model was significantly 
fit for the study.  
Table 4. 22:Overall Model Summary 
Parameters  Coefficients 
Model  1 
R . 909a 
R Square .827 
Adjusted R Square 0.821 
Std. Error of the Estimate . 036 
a. Predictors: (Constant), Quality control technology, Marketing technology, Supply 
technology 
  
Table 4. 23:Analysis of Variance 
Model Sum of Squares df Mean Square F Sig. 
Regression  78.12 3 19.52 128.12 .0.00b 
Residual   16.12 174 .085   
Total  94 .24 177    
a. Dependent Variable: Operation performance 
b. Predictors: (Constant), Quality control technology, Marketing technology, Supply technology 
The regression coefficient, the results indicate that the relationship between supply chain 
technology, marketing technology, and quality control technology was significant. This 
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relationship means that increase in any of the factors will result to significant increase in 
operation performance 
4.12.1Distribution of Coefficients in Joint Influence 
Regression was done to determine the distribution of coefficients with regard to influence of 
independent (supply chain technology, marketing technology and quality control technology) 
and dependent variable (operation performance). The influence is represented by Beta 
coefficients/weights which show the relative importance of independent variable in both 
standardized and unstandardized terms as follows: 
Table 4. 24:Distribution of Coefficients in Joint Influence 





B Std. Error Beta 
(Constant) 3.313 .297    1.425 .002 
Supply technology .316 .342 .402   8.521 .000 
Marketing technology .355 .377 .409 6.082 .000 
Quality control technology        .382 .056         0.573      6.26 .001 
a. Dependent Variable: Operation performance 
Findings in Table 4.25 indicate that there is a positive influence of supply technology on 
operation performance (β =.316). There is also positive influence of marketing technology on 
operation performance (β =.355).  Quality control performance (β = .382). Furthermore, the 
significance levels were analysed and as shown in the table, all the variables were significant. 
This simply means that 31.6% of operation performance could be explained by a unit change in 
supply technology at p= 0.000, on marketing technology the model established that 35.5% 
operation performance could be influenced by a unit change in  marketing technology and 
finally, 38.2% of quality control technology would influence operation performance at P= 
0.00./Overall, the consistency of regression coefficients on the predictors in the model suggest 
that these variables are important factors influencing operation performance. From the regression 
model the following regression equation is derived:  
Y = 3.313+.316X1+.355X2+ .382X3  
Where: Y = Operation performance 
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X1= Supply chain technology 
X2= Marketing technology 





























DISCUSSION, CONCLUSION AND RECOMMENDATIONS 
5.1 Introduction 
This chapter presents the findings presented in chapter four of the study in line with literature 
review. The main aim of this study was to analyse the influence technology on operational 
performance of pharmaceutical firms in Kenya. This chapter therefore presents summarized 
findings and linkages on empirical studies. The chapter also presents conclusion and 
recommendations.  
5.2 Discussions  
5.2.1Level of technology used by pharmaceutical firms in Kenya 
Findings on level of technology used by pharmaceutical firms in Kenya indicated that with an 
overall mean of 3.33, pharmaceutical firms in Kenya use technology highly for various activities. 
Technology is most used in making orders (mean of 4.48) followed by marketing (mean of 3.49) 
and making sales (mean of 3.45). The least use of technology is in general planning, analysis and 
reporting (mean of 3.16). From the overall mean of 3.33, the level of technology was considered 
high.  
The findings on level of technology as established in the study agree with a study by Boldeanu 
and Pugna (2012) that firms are utilising technology-based intelligence framework to improve 
integration of business intelligence initiatives. According to Boldeanu and Pugna (2012) 
pharmaceutical firms use technology highly in research, interaction with Healthcare providers 
and patients to even healthcare systems in different markets. Also, the findings of this study are 
in agreement with Abdolvand, Albadvi and Ferdowsi (2012) that pharmaceutical companies are 
highly leveraging technology to go further and faster in monitoring patient safety. Placed in the 
context of adoption of technology, this study supports the Technology Acceptance Model (TAM) 
that organisations adopt technologies easily with intention of applying in several activities. This 







5.2.2 Supply chain technology on the operational performance of pharmaceutical firms in 
Kenya 
Findings on influence of supply chain technology on operational performance indicated that 
firms use technology to perform supply chain activities. The activities include sharing 
information regarding supplies on electronic network that include emails. Also, the firms use 
MRP systems to harmonise forecasting, procurement, production and sales. The least use of 
technology regarding supply chain is the interconnection between departments. With an overall 
mean of 3.21, the findings imply that technology was intensively used in all stages of supply 
chain mainly planning, implementation and reporting.  
The R-Square 0.665 which means that 66.5% variation in operation performance in 
pharmaceutical firms is caused by supply chain technology whereas 33.5% variability is caused 
by other factors. Analysis of Variance (ANOVA) consists of calculations that provide 
information about the level of variability within the regression model and forms the basis for 
tests significance. The F column provides the basis for testing the hypothesis between the 
alternative and null hypothesis. From the table, the significance value is less than 0.05 thus 
indicating that the model is statistically significant in predicting how supply chain technology 
influence operation performance of pharmaceutical industries in Kenya. Regression results, 
holding Supply chain Technology constant at zero, operation performance of pharmaceutical 
firms would be 4.313. A unit increase in supply chain technology would lead to a 0.65 increase 
in operation performance of pharmaceutical firms in Kenya. At 5% significance level, supply 
chain technology had 0.0025 which is less than p< 0.05 and therefore it can be concluded that 
supply chain technology positively and significantly influences operation performance of 
pharmaceutical firms to a large extent. 
In general, supply chain technology has no significant influence on operational performance 
among pharmaceutical firms in Kenya. The findings of the study are therefore not in agreement 
with Vivarelli (2015) who established that technological innovations deployed in the 
pharmaceutical industry in Europe had led to may be direct labor saving through increased 
efficiency and productivity with the most notable changes noted in the supply chain of drugs and 
other pharmaceutical products.  
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The findings of this study also differ with findings by Munyasi (2015) who established that 
pharmaceutical companies that embraced new technologies had a competitive edge in sourcing 
and distribution of drugs due to the reduction in the costs associated with transportation, 
coordination and storage of products. The findings of this study do not support other empirical 
studies indicate that diffusion of technology has enabled pharmaceutical firms to solve 
challenges in the supply chain. This study therefore differs with the Diffusion of innovation 
(DOI) theory that the technologies adopted are compatible to business processes hence 
significant influence on operation performance.  
5.2.3 Marketing technology on the operational performance of pharmaceutical firms in 
Kenya 
Findings on influence of marketing technology on operation performance indicate that marketing 
technology is used to increase brand image on social media platforms (mean 3.34), research 
(mean of 3.33) and market awareness (mean of 3.30). Other uses of technology in marketing 
include monitoring and reporting. With an overall mean of 3.23, the findings imply that 
technology is highly utilised in marketing operations. The operations are both internal (planning 
and control) and external (interactions with consumers).  
While establishing the relationship between marketing technologies R-Square 0.336 which 
means that 33.6% variation in operation performance of pharmaceutical firms is due to the use of 
marketing technology with 66.4% being cause by other factors which is outside this model which 
is not marketing technology. ANOVA comprise of calculations that provide information about 
the level of variability within a regression model and usually forms the basis for conducting tests 
of significance. The F column normally provides the basis for testing both null and alternative 
hypothesis of the variable. For instance, in the table the significance value is 0.000 which is less 
than 0.05 thus the model is statistically significant in predicting how marketing technology 
influences operation performance of pharmaceutical firms in Kenya. Based on the regression 
results, holding marketing technology constant at Zero, operation performance of pharmaceutical 
firms would be 4.709. A positive unit change in marketing technology would lead to a 0.719 
increase in operation performance of pharmaceutical firms in Kenya. At 5% confidence level, 
marketing technology had p= 0.000 which is less than 0.05 and hence the study can conclude that 
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marketing technology positively and significantly affecting operation performance of 
pharmaceutical firms in Kenya to a great extent 
The findings are therefore largely disagreeing with Kor and Mahoney (2005) and Khedkar 
(2015) who established that marketing technology helps pharmaceutical firms to build 
interactions with customers and other stakeholders. The significant benefit of marketing 
technology therefore does not necessarily support the Technology Acceptance Model (TAM) 
that organizations which perceive technologies will improve overall performance end up 
adopting the technology. It is not therefore guaranteed that organizations that perceive that any 
technology if applied will reduce costs and deployment of more resources eventually adopt such 
technology. Thus, acceptance of marketing technology by pharmaceutical firms in Kenya does 
not necessarily increase performance where costs are reduced.  
5.2.4 Quality control technology on the operational performance of pharmaceuticals firms 
in Kenya 
Findings on influence of quality control technology on operation performance indicated that with 
an overall mean of 2.97, the findings technology supports quality control activities. The most 
utilised activities are automation of drug registry (mean of 3.26), followed by training (mean of 
3.21), tracking of inventories (mean of 3.20), testing (mean of 3.16). Other quality control 
activities in which technology is used include fulfilment of regulatory technology (mean of 3.12) 
and reporting (mean of 3.11). With an overall mean of 3.18, the findings imply that technology 
supports quality control activities. The findings also indicate that the pharmaceutical firms derive 
benefits from using technology in quality control operations.  
 In testing the relationship between quality control technology and operation performance the 
value for R-Square is 0.4356 which simply means that 43.56% of the variation in operation 
performance is due to variation in quality control technology meaning that 56.44% of the 
variation in operation performance of pharmaceutical firms is due to other factors other than 
quality control technology.  
Analysis of Variance (ANOVA) consists of calculations that provide information about the 
levels of variability within the regression model and form a basis for tests of significance. The F 
column provides a statistic for testing hypothesis. From the findings, the significance value is 
0.000 which is less than 0.05 thus it can be deduced that the model is statistically significant in 
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predicting how quality control technology influences operation performance of pharmaceutical 
firms in Kenya.   
Based on the regression results shown, holding quality control technology constant zero, 
operation performance of pharmaceutical firms in Kenya would be 4.231. A positive unit change 
in quality control technology would lead to 0.635 increase in operation performance. At 5% 
significance level, quality control technology had p= 0.0025 which is less than 0.05 and hence 
the study can deduce that quality control technology significantly and positively affects the 
operation performance of pharmaceutical firms in Kenya. 
These findings are therefore not in agreement with Guzman (2010) that pharmaceutical 
companies are under significant pressure to both innovate and successfully manage increasingly 
complex operations, more stringent regulatory requirements and frequent consolidations. 
According to Guzman (2010), there is high chance of restricted regulations inhibiting 
performance. WHO (2016) also agrees that while the benefits are clear, a misalignment between 
the QMS and a company’s operational requirements can have downsides and impact on costs.  
The negative influence of the quality control measures on operation performance reveal that 
diffusion of technology can therefore be slow due to uncertainties and perceptions of the 
organisations towards some effects of the technology on overall performance. The findings 
therefore agree with the Diffusion Theory that if pharmaceuticals are at persuasive level, there is 
likelihood of slow adoption. In addition, the findings of this study are in concurrence with 
Technology Acceptance model that organisations which perceive that technology will have 
negative influence on overall performance, are likely not to adopt the technology.  
Linearity test was done to determine whether relationship between independent variables (supply 
chain technology, marketing technology and quality control technology) and dependent variable 
(operation performance) were linearly related. The results showed that the Deviation from 
Linearity value of 0.298 for the relationship between supply chain technology and operation 
performance is >0.05. Also, the findings indicate that the Deviation from Linearity value of 
0.409 for the relationship between marketing technology and operation performance is >0.05. In 
addition, the findings indicate that the Deviation from Linearity value of 0.415 for the 
relationship between quality control technology and operation performance is >0.05. As the all 
the Deviation from Linearity values are >0.05, the findings imply that there is linear relationship 
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between independent variables (supply chain technology, marketing technology and quality 
control technology) and dependent variable (operation performance). In this regard, any 
significant change in supply chain technology, marketing technology and quality control 
technology results into proportionate change in operation performance. 
 
Normality tests according to Wheeler (2001) is useful since it helps to confirm whether the data 
follows a normal distribution. In cases where normality is violated, the results may fail to reflect 
a true picture of the relationship among the variables in the study. In this study normality was 
tested using Shapiro –Wilk tests which is considered most appropriate for small samples < 500 
samples. In using this tests procedure, when significance value is less than 0.05 then the data 
significantly deviates from normality and therefore appropriate procedure to perform data 
transformation to observe normality must follow before running parametric tests statistics.  
The findings are illustrated in  
 
The table shows that significance value for Shapiro- Wilk tests were 0.267 for supply 
technology, marketing technology 0.478 and 0.350 for quality control technology. Since p- 
values for Shapiro walk tests for all the variables were greater than 0.05 then we can accept null 
hypothesis that the data came from normally distributed population and therefore parametric tests 
statistics were considered ideal and therefore inferential statistics of persons correlations and 
multiple linear regression was considered permissible 
 
Multicollinearity is a test that evaluates whether the independent variables are highly correlated. 
The primary concern is that as the degree of multicollinearity increases, the general regression 
model estimates of the model becomes unstable and the standard errors for the coefficients can 
get wildly inflated. Multicollinearity in this study was tested using Variance Inflation Factor 
(VIF). For the purpose of this study VIF less than 3 (VIF<3) means that no multicolliearity exists 
between the variables and (VIF> 3) means that there are multicollinearity which calls for 
correction before proceeding with testing for inferential tests statistics (Maddala & Lahiri, 1992).  
In the multicollinearity table, is shows that there was no multicollinearity among the independent 
variables since the VIF was less than the threshold of value 3. The results showed that VIF for 
supply technology 1.5, marketing technology 2.494 and Quality control technology 1.301. There 
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was no similarity between the independent variables with operational performance which would 
interfere with interpreting the model equation.  In this study homoscedasticity was tested using 
Breuch- Pagan/ Cook Weisberg test. For this test the null hypothesis is that the error variances 
are all equal while the alternative hypothesis is that the error variances are multiplicative 
function of one or more variables. In making decision whether a given population demonstrate 
homoscedasticity, p – values should be equal to or same as 0.05 (Bera & Jarque, 2012). The 
results show that the constant variance (Chi2 = 12.12) is insignificant (p= 0.153). Thus, we fail to 
reject null hypothesis and conclude that the error variance is equal thus homoscedasticity is 
evidence in the study data. In such a case, we therefore accept the null hypothesis that there is no 
difference in residual variance of independent to dependent variables tested in the dataset.  
The results of the Persons correlation indicate that there is significant positive correlation 
between supply chain technology, marketing technology, and quality control with operation 
performance. Correlation analysis was done to determine the strength of relationship between 
supply chain technology and operation performance, marketing technology and operation 
performance and quality control technology and operation performance. The results of persons 
correlation coefficient indicates that there is a significant positive correlation between supply 
chain technology, marketing technology and quality control technology and operation 
performance whereas ( r = 0.61, p value < 0.05; a significant positive correlation between 
marketing technology with operation performance ( r = 0.58* , p value is less than 0.05; and 
positive significant correlation between quality control technology and operation performance ( r 
= 0.66* , p = 0.00). Overall, the study indicates that independent variable (supply chain 
technology, marketing technology and quality control technology) had positively moderately 
stronger association with dependent variables. This simply implies that any positive changes in 
supply chain technology, marketing technology and quality control technology would enhance 
operation performance of pharmaceutical industries. The above R Square is 0.665 which means 
that 66.5 % variation in operation performance in pharmaceutical industries is caused by supply 
chain technology by 33.5% variability being caused by other factors which are not attributed to 
supply chain technology.  
 
Analysis of Variance (ANOVA) consists of calculations that provide information about the level 
of variability within the regression model and forms the basis for tests significance. The F 
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column provides the basis for testing the hypothesis between the alternative and null hypothesis. 
From the table, the significance value is less than 0.05 thus indicating that the model is 
statistically significant in predicting how supply chain technology influence operation 
performance of pharmaceutical industries in Kenya.  
 Based on the regression results, holding Supply chain Technology constant at zero, operation 
performance of pharmaceutical firms would be 4.313. A unit increase in supply chain technology 
would lead to a 0.65 increase in operation performance of pharmaceutical firms in Kenya. At 5% 
significance level, supply chain technology had 0.0025 which is less than p< 0.05 and therefore it 
can be concluded that supply chain technology positively significantly influences operation 
performance of pharmaceutical firms.  
 
The value of R-Square is 0.336 which means that 33.6% variation in operation performance of 
pharmaceutical firms is due to the use of marketing technology with 66.4% being cause by other 
factors which is outside this model which is not marketing technology. ANOVA comprise of 
calculations that provide information about the level of variability within a regression model and 
usually forms the basis for conducting tests of significance. The F column normally provides the 
basis for testing both null and alternative hypothesis of the variable. For instance, in the table the 
significance value is 0.000 which is less than 0.05 thus the model is statistically significant in 
predicting how marketing technology influences operation performance of pharmaceutical firms 
in Kenya.  
Based on the regression results, holding marketing technology constant at Zero, operation 
performance of pharmaceutical firms would be 4.709. A positive unit change in marketing 
technology would lead to a 0.719 increase in operation performance of pharmaceutical firms in 
Kenya. At 5% confidence level, marketing technology had p= 0.000 which is less than 0.05 and 
hence the study can conclude that marketing technology positively and significantly affecting 
operation performance of pharmaceutical firms in Kenya to a great extent.  
According to the table, the value for R-Square is 0.4356 which simply means that 43.56% of the 
variation in operation performance is due to variation in operation performance meaning that 
56.44% of the variation in operation performance of pharmaceutical firms is due to other factors 
other than quality control technology. Analysis of Variance (ANOVA) consists of calculations 
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that provide information about the levels of variability within the regression model and form a 
basis for tests of significance. The F column provides a statistic for testing hypothesis. From the 
findings, the significance value is 0.000 which is less than 0.05 thus it can be deduced that the 
model is statistically significant in predicting how quality control technology influences 
operation performance of pharmaceutical firms in Kenya.   
Based on the regression results shown, holding quality control technology constant zero, 
operation performance of pharmaceutical firms in Kenya would be 4.231. A positive unit change 
in quality control technology would lead to 0.635 increase in operation performance. At 5% 
significance level, quality control technology had p= 0.0025 which is less than 0.05 and hence 
the study can deduce that quality control technology significantly and positively affects the 
operation performance of pharmaceutical firms in Kenya.  
A regression analysis of the overall model was performance. The results for the overall summary 
was presented. The study findings indicated that supply chain technology, marketing technology 
and quality control technology are positively associated with operation performance of 
pharmaceutical firms in Kenya as indicated by Person correlation R value of 0.909. 
Consequently, the proportion of the variance explained by R- Square which is 0.825. This simply 
means that 82.5% of operation performance is explained by combined effects of supply chain 
technology, marketing technology and quality control technology. From the ANOVA results the 
study confirmed the model fitness by comparing the F critical values where F value of 126.014 
which is significant at 0.000 which is less than 0.05. This shows that the model was significantly 
fit for the study.  
b. Predictors: (Constant), Quality control technology, Marketing technology, Supply technology 
The regression coefficient, the results indicate that the relationship between supply chain 
technology, marketing technology, and quality control technology was significant. This 
relationship means that increase in any of the factors will result to significant increase in 
operation performance. Regression was done to determine the distribution of coefficients with 
regard to influence of independent (supply chain technology, marketing technology and quality 
control technology) and dependent variable (operation performance). The influence is 
represented by Beta coefficients/weights which show the relative importance of independent 
variable in both standardized and unstandardized terms as follows: 
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Findings indicate that there is a positive influence of supply technology on operation 
performance (β =.316). There is also positive influence of marketing technology on operation 
performance (β =.355).  Quality control performance (β = .382). Furthermore, the significance 
levels were analysed and as shown in the table, all the variables were significant. This simply 
means that 31.6% of operation performance could be explained by a unit change in supply 
technology at p= 0.000, on marketing technology the model established that 35.5% operation 
performance could be influenced by a unit change in  marketing technology and finally, 38.2% 
of quality control technology would influence operation performance at P= 0.00. Overall, the 
consistency of regression coefficients on the predictors in the model suggest that these variables 
are important factors influencing operation performance. From the regression model the 
following regression equation is derived:  
5.3 Conclusion 
The study concluded that pharmaceuticals in Kenya have indeed employed technologies. The 
expectation of the pharmaceuticals in Kenya is for the technologies to improve operation 
performance either individually or joint. The findings of this study have indicated that individual 
influence of supply chain technology, marketing technology and quality control technology is 
positive and significant. The high performance of operation in pharmaceuticals in Kenya is 
realised when there is joint influence of supply chain technology, marketing technology and 
quality control technology. The joint influence is significant and strong as opposed to individual 
parameters. 
5.4 Recommendations 
The following are recommendations of the study:  
5.4.1 Supply chain technology  
The researcher recommends to pharmaceutical firms operating in Nairobi to enhance the use of 
supply chain technology since it has positive and significant influence on operation performance 
of pharmaceutical companies. Supply chain department is very essential and therefore looking 
for ways of automating the processes and giving customers excellent experience in delivery 
because of technology is the supply chain should be a top priority in every firm interested to 
scale up the bottom line.  
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5.4.2 Marketing Technology  
The researcher recommends pharmaceutical firms to use more often technology in their pursuit 
to enhance operational performance since marketing is critical to the success of the firm. By 
adopting online platform and embracing technology in marketing, the results of inferential 
statistics proved significant positive relationship.  
5.4.3 Quality Control Technology  
 Pharmaceutical firms should maintain quality control technologies. The quality control 
technologies ensure compliance and improvement in customer needs. However, the negative 
influence should be compensated by improving uptake of other technologies.  
5.5 Suggestions for Further Studies 
This study looked at influence of technology on operational performance of pharmaceutical firms 
in Kenya, other studies could look at other aspects of performance such as employee 
performance, and performance of macro environmental factors on pharmaceutical firms in 
Kenya. 
 The operationalization of technology was based on three aspects: supply chain, marketing and 
quality control. Further studies could be done that look at other dimensions of technology e.g. 
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Appendix 1: Letter of Introduction 
APPENDIX II-QUESTIONNAIRE 
INFLUENCE OF TECHNOLOGY ON THE OPERATIONAL PERFORMANCE OF 
PHARMACEUTICAL FIRMS IN KENYA. 
The purpose of this survey is to seek your opinions on the various technologies deployed by 
pharmaceutical firms in Kenya. It purely for the purpose of academic work that is assessing how 
these technologies influence operational performance of pharmaceutical firms. Feel free to 
respond as you wish since there is no right or wrong answers.  Please fill out the questionnaire in 
the spaces below. Kindly tick [√] only one response in the spaces provided. 
 
SECTION A: BACKGROUND INFORMATION 
1. Name of your firm (Optional) _____________________ 
2. What is your department  
Supply chain [ ] Marketing   [ ]  Quality control [ ] Operation [ ] 
3. Duration in Employment  
1 -4 years  [ ] 4-8 years  [ ]  
8-12 years [ ] 12 years and above [ ]  
4. Firm’s major functions (multiple response)? 
Manufacturing [ ]  Distribution [ ] Customer care [ ]  
Marketing        [ ]  Quality control [ ] Advocacy [ ] 
Others [ ] (please explain) _____________________________________________________  
SECTION B: LEVELS OF TECHNOLOGIES USED 
Below are several statements on levels of technologies of pharmaceutical firms. Please indicate 
the extent to which they apply to your organization on a Likert Scale of 1 to 5 where 1=Strongly 
Disagree=1, 2=Disagree, 3=Neutral, 4=Agree and 5=Strongly Agree 
STATEMENT 1 2 3 4 5 
The firm uses technology in receiving or making orders.      
The firm uses technology in making sales (taking customer requests, 
payment and dispensing drugs). 
     
The firm uses technology in marketing      
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The firm uses technology in advising members of the public and 
customers on drugs and usage. 
     
The firm uses technology in managing inventories.      
Any other (specify)      
 
 
SECTION C: SUPPLY CHAIN TECHNOLOGY 
Below are several statements on supply chain technology of pharmaceutical firms in Kenya. 
Please indicate the extent to which they apply to your organization on a Likert Scale of 1 to 5 
where 1=Strongly Disagree=1, 2=Disagree, 3=Neutral, 4=Agree and 5=Strongly Agree 
Indicator STATEMENT 1 2 3 4 5 
Distributor 
RM tools 
The firm uses technology in planning and developing 
supply chain needs. 
     
The firm shares information with suppliers through 
the electronic network 
     
The firm and its suppliers relate to an electronic 
system to control inventory 
     
The firm uses an MRP system (to harmonize 
forecasting, procurement, production and sales) 
     
The firm’s internal departments are electronically 
interconnected 
     
       
The firm uses technology to ensure product 
availability JIT 
     
The firm employs technology to collect customer 
feedback to improve its supply chain.  
     
The firm employs technology to collect customer 
feedback to improve products.  
     
Any other 
(specify) 




SECTION D: MARKETING TECHNOLOGY 
5. Below are several statements on marketing technology and how it influences the operational 
performance of pharmaceutical firms in Kenya. Please indicate the extent to which they 
apply to your organization on a Likert Scale of 1 to 5 where 1= No extent, 2= little extent, 
3=moderate extent, 4=great extent and 5=very great extent. 
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Indicator  STATEMENT 1 2 3 4 5 
Social media The firm uses social media (Facebook, Twitter and You 
Tube) to actively market its products 
     
Technology has reduced the firm’s marketing budget      
The firm uses social media to receive customer feedback 
about a product.  
     
Social media is used to create market awareness about 
new products.  
     
Webinars  
 
Company has a data base of relevant physicians for its 
product portfolio 
     
The company uses webinars and e-conferencing to 
capacitate physicians 
     
The company anchors on technology to support its 
exposes 





The company uses technology to segment the consumer 
markets 
     
The company monitors the market using technology      
The company uses Technology to articulate its unique 
selling perspective (USP) 
     
Any other 
(specify) 
      
 
SECTION E: QUALITY CONTROL TECHNOLOGY 
6. Below are several statements on quality control technology and how it influences the 
operational performance of pharmaceutical firms in Kenya. Please indicate the extent to 
which they apply to your organization on a Likert Scale of 1 to 5 where 1= No extent, 2= 
little extent, 3=moderate extent, 4=great extent and 5=very great extent. 
STATEMENT 1 2 3 4 5 
The firm has automated its drug registry      
The firm has a control tracking system to keep the inventory valid      
The firm trains staff and agents on latest industry innovations and trends      
The firm anchors on technology to meet its regulatory mandate      
The firm relies on technology for testing of new molecules      
The firm uses technology to maintain just in time responses from end users      




SECTION F: OPERATIONAL PERFORMANCE 
7. Operational performance refers to the level of effectiveness and efficiency of a firm in 
operations such as marketing, distribution and quality control. To what extent do you agree 
with the following statements? Please indicate the extent to which they apply to your 
organization on a Likert Scale of 1 to 5 where 1=Strongly Disagree=1, 2=Disagree, 
3=Neutral, 4=Agree and 5=Strongly Agree 




Supply chain technology has increased timely delivery 
of products to customers.   
     
Marketing technology has enabled us to improve 
product awareness for customers in the market  
     
Supply chain technology has improved time of serving 
customers 
     
Supply chain technology has increased level of 
obtaining customer compliments and complaints. 
     
Supply chain technology has increased level of 
responding to customer compliments and complaints. 
     
Cost controls 
 
Marketing technology has supported increase in 
revenues.  
     
Marketing technology has reduced costs of marketing 
activities.  
     
Supply chain technology has reduced costs of supply 
chain operations. 
     




Quality control technology has increased the firm’s 
ability to respond to customer/ market demands 
     
Quality control technology has improved satisfaction 
levels of customers. 
     
Quality control technology has aided the firm’s ability 
to meet regulatory demands 
     
Quality control technology has improved the overall 
product and service quality offering by introducing 
global standards. 
     
Any other 
(specify) 
      
 




APPENDIX III-LIST OF PHARMACEUTICAL MANUFACTURING COMPANIES IN 
KENYA 
1. Apple Pharmaceuticals Ltd 
2. Benmed 
3. Biodeal laboratories  
4. Elys Chemicals 
5. Beta Healthcare  
6. Astra Zeneca 
7. Pfizer Laboratories 
8. Johnson & Johnson 
9. Servier 
10. Kam Industries 
11. Novartis Pharmaceuticals 
12. Sanofi 
13. Merck Consumer Health & Life Science 
14. Lords Healthcare 
15. Indoco Remedies 
16. Cipla Medpro 
17. Cadilla Healthcare 
18. C.Mehta & Company 
19. Phillips Pharmaceuticals  
20. Ely Lilly 
21. Merck Schering Plough 
22. Novelty Manufacturing 
23. Simba Pharmaceuticals  
24. Biopharm 
25. Bayer East Africa 
26. Glaxo Smithkline  
27. Concepts (Africa) Ltd 
28. Cosmos Ltd Cosmos Limited 
29. Lab & Allied  
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30. Gesto Pharmaceuticals 
31. Pharmaceutical Manufacturing Ltd – PMC 
32. Universal Corporation Ltd 
33. Dawa Company  
34. Sphinx Pharmaceuticals Ltd 
35. Square Pharmaceuticals 
36. Statim  
37. MACs Pharmaceuticals  
38. Medina Chemicals 
39. Nairobi Enterprises 
40. Laborex Kenya Ltd 
41. Diddy Pharmaceuticals 
42. Dafra 
43. Unisel  
44. Medisel 
45. Armicon 
46. SynerMed Pharmaceuticals  
47. Norbrook Kenya Limited 
48. Surgilinks Pharmaceuticals  
49. Comet Healthcare  
50. Regal Pharmaceuticals  
 
Source: Pharmacy & Poisons Board – Manufacturer registration renewal list 2019 
 
